NPR

Biological Targets and Mechanisms of Action of Natural Products from Marine Cyanobacteria

SCHOLARONE™
Manuscripts

NPR

ARTICLE

Biological Targets and Mechanisms of Action of Natural Products from Marine Cyanobacteria

Lilibeth A. Salvador-Reyes,[a,c] and Hendrik Luesch*[a,b]

Marine cyanobacteria are an ancient group of organisms and prolific producers of bioactive secondary metabolites. These compounds are presumably optimized by evolution over billions of years to exert high affinity for their intended biological target in the ecologically relevant organism but likely also possess activity in different biological contexts such as human cells. Screening of marine cyanobacterial extracts for bioactive natural products has largely focused on cancer cell viability; however, diversification of the screening platform led to the characterization of many new bioactive compounds. Targets of compounds have oftentimes been elusive if the compounds were discovered through phenotypic assays. Over the past few years, technology has advanced to determine mechanism of action (MOA) and targets through reverse chemical genetic and proteomic approaches, which has been applied to certain cyanobacterial compounds and will be discussed in this review. Some cyanobacterial molecules are the most-potent-in-class inhibitors and therefore may become valuable tools for chemical biology to probe protein function but also be templates for novel drugs, assuming in vitro potency translates into cellular and in vivo activity. Our review will focus on compounds for which the direct targets have been deciphered or which were found to target a novel pathway, and link them to disease states where target modulation may be beneficial.

1 Introduction

Natural products have historically been utilized to develop new drugs, and it remains to be one of the most successful approaches to find small molecules for the drug discovery pipeline. Approximately 50% of new drugs introduced from 1981–2010 were derived from Nature, the majority being antiproliferative agents and antibiotics.[1] The discovery of small molecule therapeutics can be undertaken using either a target-based (reverse genetics) or a phenotypic-based (forward genetics) approach.[2] In the target-based approach, purified proteins with disease-relevance are utilized to screen for modulators of activity.[3] This screening approach has the advantage of knowing the direct target of the small molecule; however, it poses the possibility of the *in vitro* activity not translating to *in vivo* potency and the cellular effects being defined later in the drug discovery process.[2,3] Since target-based screening is usually done in cell-free systems, it has limited utility for discovery of prodrugs and in providing preliminary insights on the pharmacokinetic properties of small molecule hits. Several of the limitations in target-based

screening are addressed by employing phenotypic-based assays. Relying on phenotypic assays, however, complicates the search for the cellular targets of small molecules and continues to be a bottleneck for this approach.[2,4] Equally important to defining the potency of natural products, discovered using either method, is determining unintended off-targets, which is critical to predicting possible side effects. Since natural products are regarded as privileged structures, capable of binding to multiple proteins with unrelated structures, these small molecules may have multiple targets.[5] Rigorous characterization of cellular targets and mechanism of bioactivity is then necessary to achieve a comprehensive assessment of the potency, efficacy and pharmacology of bioactive small molecules. Natural products have been central to the discovery of novel drug targets and represent a unique source of chemical probes to investigate proteins and signaling networks.[6] For example, the natural products trapoxin[7] and trichostatin A[8,9] were pivotal to elucidating the structure and functional role of histone deacetylases (HDACs). An affinity matrix based on trapoxin B, K-trap, allowed for the purification of HDACs from bovine thymus and permitted the molecular characterization of HDACs.[7] Trichostatin A, on the other hand, was instrumental to

the structural analysis of HDACs, providing the first X-ray cocrystal structures of histone deacetylase-like proteins and HDAC8, crucial in defining the critical structural elements of HDACs for pharmacological interventions.[8,9] These discoveries were instrumental to revolutionizing epigenetics and in defining the role of HDACs in cancer. Today, HDACs represent a novel molecular target and mechanism to modulate malignancies and are also being pursued for non-cancer diseases where gene expression changes may be beneficial.[10]

Proteins represent the majority of molecular targets of marketed drugs, with enzymes and G-protein coupled receptors accounting for almost 75% of these molecular targets.[11] In contrast, non-protein targets such as DNA, RNA, ribosomes, metabolites and physicochemical mechanisms represent only close to 5% of the molecular targets of marketed drugs.[11] The rest of the molecular targets of marketed drugs include ion channels, transport proteins and non-GPCR receptors. The overrepresentation of proteins as druggable targets and challenges in exploiting non-protein targets have initiated protein-centric experimental methods for target identification that are geared towards interrogating the proteome as well as the genome and transcriptome, in relation to protein expression and the observed phenotypic effects and MOA.[2,4,11,12] In recent years, significant improvements in the omics technologies, specifically genomics, transcriptomics and proteomics, have allowed for the systematic and unbiased assessment of the molecular targets of small molecules. These techniques have been demonstrated to be amenable for mammalian cellular systems as well as for model organisms such as *Saccharomyces cerevisiae* (yeast), *Caenorhabditis elegans* (nematode worm) and *Danio rerio* (zebrafish).[2,4,11,12]

Cyanobacteria, or blue-green algae, represent a unique source of small molecules since these organisms are believed to be the most ancient organisms on Earth and may thus represent chemical factories with highly evolved machineries for secondary metabolite production. In addition, cyanobacteria are also known to affect the biosynthesis of compounds from marine invertebrates such as sponges, ascidians and shell-less mollusks through either endosymbiosis or diet-derived enrichment.[13–15] A survey of natural products with FDA approval and those in clinical trials indicated that ~20% of these small molecules are likely to have cyanobacteria as predicted biosynthetic sources.[16] Cyanobacteria are also a validated source of new drugs, with the FDA-approved antibody-drug conjugate brentuximab vedotin (Fig. 1), inspired from the cyanobacteria compound dolastatin 10.[17]

Fig. 1

Cyanobacteria as source organisms may then represent a treasure chest of new small molecules that can potentially be tapped for biomedical and pharmacological applications, either as drug leads or chemical probes.[18–20] The majority of these small molecules was derived using bioactivity-guided purification, showing diversity of chemistry and biological activity.[18–20] The true value of this resource may be fully realized with rigorous studies on the MOA to define the intended therapeutically-relevant and possible cellular off-target effects. In this review, we examine cyanobacterial small molecules with established molecular targets and MOA and discuss future prospects for several of these potent pharmacological agents.

2 Methods in Target Identification and Elucidation of Mechanism of Action

Insights into the direct cellular target of small molecules have typically been derived from target-based assays, chemical structure and phenotypic response similarity to other small molecules with defined MOA. These methods, however, have limited utility for small molecules with novel chemical structures and MOA. The last twenty years have seen a revolution in the development of global and unbiased methods to elucidate the direct target and MOA of small molecules. These methods are complementary to one another and should be used hand-in-hand to provide a comprehensive picture of the cellular consequences of small molecule treatment. Variants of several of the techniques discussed in this section have also been applied to determine targets and MOA of natural products from marine cyanobacteria (Fig. 2). In addition, hits derived from both indirect and direct techniques for target identification should be rigorously validated using biochemical evaluation and/or X-ray cocrystallography studies.

Fig. 2

2.1 Indirect Approach

One of the earliest comprehensive approaches to elucidating the MOA of natural products is through the National Cancer Institute (NCI) 60 cell line screen (NCI-60) and COMPARE algorithm.[21] This is based on the similarity in phenotypic response for structurally unrelated small molecules, with similar MOA.[21] The NCI-60 screen employs measurement of the antiproliferative effects of small molecules against a panel of 60 tumor cell lines consisting of leukemia, small cell lung, non-small cell lung, colon, central nervous system, melanoma, ovarian, and renal. The differential cytotoxicity of the small molecule towards each cell line is evaluated and plotted to obtain a "fingerprint". This "fingerprint" differential cytotoxicity profile is compared to the extensive database of previously screened small molecules of NCI using the COMPARE algorithm.[21] Compounds with unique differential cytotoxicity profile are likely to possess a novel MOA, while compounds with similar MOA can be clustered together.[21] The utility of this method was first demonstrated for halichondrin B.[22] The differential NCI-60 profile of halichondrin B showed striking similarity with the known antimitotic agent maytansine, indicating analogous MOA.[22] Drug susceptibility can be correlated with the unique gene expression profiles of the cell lines and compounds thus linked to molecular target and modes of resistance.[23–25] While this approach has been successfully utilized for several natural products, this is obviously limited for small molecules with significant antiproliferative effects towards cancer cells. Also, the NCI-60 screen provides information on the MOA, rather than the direct target. This method provides little information on the MOA of small molecules with potentially unique MOA.

The principle of the NCI-60 screen has been expanded, using high content screening, to provide insights into the MOA of

prefractionated extract libraries of natural products and for identification of compounds with possible novel bioactivity or chemistry. The high-content cell morphology database Morphobase utilizes similarity in chemical-genetic phenotype of cancer cell lines treated with small molecules for rapid target identification.[26]

The MOA of small molecules has also been interrogated via the transcriptome. Microarray analysis has been used to monitor global changes in transcript levels of mammalian cells, in response to small molecule treatment. Changes to the transcriptome, together with a network analysis of significantly modulated transcripts provide insights into the MOA of the small molecule.[27] Recent progress in next-generation sequencing technology has also allowed for the comprehensive and unbiased profiling of the transcriptome of resistant colonies of mammalian tumor cells derived from prolonged exposure to small molecule treatment.[28] The observed resistance was demonstrated to arise from mutations in the small molecule target and/or overexpression of drug efflux pumps.[28] These mutations were limited to single nucleotide variations and short insertions and/or deletions present in the coding sequences.[28] The utility of transcriptome profiling for target identification was successfully demonstrated as proof-of-concept for bortezomib and BI-2356.[28] Five bortezomib-resistant clones were isolated and transcriptome analysis indicated 15–28 single nucleotide variations in five genes. The highest frequency in mutation was observed for *PSMB5*, which encodes for the proteasome, thus validating this new method for target identification.[28] Other changes in the transcriptome of resistant cells, independent of the drug target or the drug efflux transporters were, however, not completely elucidated in this seminal paper. Modulating transcript levels either via cDNA overexpression or siRNA-mediated mRNA knockdown has also been utilized to elucidate the target of small molecules.[29] This method relies on the correlation between transcript and protein levels such that overexpression would lead to an increase of the target protein, while silencing of the target gene will cause a corresponding decrease or depletion of target protein.[29] Changes in the level of the target protein will lead to either resistance or susceptibility to the small molecule treatment, arising from overexpression or silencing, respectively.[29]

2.2 Direct Approach

Interrogation of the direct target of small molecules relies on chemical proteomics – combination of affinity chromatography and mass spectrometry – for purification and identification of direct binding proteins.[2] The success of affinity chromatography is dependent on the binding affinity of the small molecule and the abundance of the target protein.[2,30] Small molecules with high affinity for their target are generally favored for affinity-based purification. While the binding affinity of small molecules may not always be directly correlated to the IC_{50} or EC_{50}, compounds with nanomolar IC_{50}s are ideal for affinity chromatography.[30]

Affinity chromatography requires the immobilization of the small molecule on a solid support such as sepharose beads and,

hence, necessitates chemical derivatization of the small molecule.[30] Extensive structure-activity relationship (SAR) studies are required to determine the appropriate site for modification, which does not significantly affect the biological activity of the small molecule. Affinity chromatography is then prohibitive for very small molecules with no appropriate sites for chemical modification. For natural products with limited amounts and not readily prepared through chemical synthesis, the choice of derivatization site may be limited to functional groups that can easily be modified such as terminal alkynes which rapidly and selectively react in a $CuSO_4$-catalyzed azide-alkyne cycloaddition click chemistry. A linker moiety bridges the small molecule to the solid support and is required not solely for immobilization but also to avoid steric interference of matrix and target protein.[4] Common linkers include polymethylene, polyethylene and polyproline chains with varying lengths.[4]

The pulldown affinity probe is incubated with either prefractionated or whole cell lysates, the former providing preliminary enrichment of proteins localized in specific cellular compartments.[4] After incubation, the probe is washed extensively to remove non-specific binding proteins. This is the crucial step in affinity purification and dependent on the balance of the affinity of the small molecule for its target and the abundance of the protein target.[30] Captured proteins are monitored using gel electrophoresis and/or mass spectrometric analysis. In order to differentiate nonspecific binding proteins from the bona fide small molecule target, competition experiments and a control probe may be utilized. For competition experiments, excess amounts of the unmodified small molecule are added to the cell lysates.[4] The unmodified small molecule will then compete with the probe for the target protein; hence, a lower amount of a real hit will be captured.[4] The use of a control probe, on the other hand, entails design of a pulldown probe based on an inactive analog of the small molecule.[4] The direct target is unable to bind to the control probe and thus significant enrichment of the real protein target will be observed in incubations using the bioactive probe. A combination of affinity chromatography with mass spectrometry-compatible labeling techniques such as stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tag for relative and absolute quantitation (iTRAQ) has also been utilized to differentiate nonspecific binding proteins from the real direct target of small molecules.[31] SILAC utilizes either natural (light isotope) or $^{13}C_6$-labeled (heavy isotope) lysine during cell culture and, in the process of translation, will be incorporated into proteins. The proteins labeled with the light isotope are incubated with the affinity probe, while proteins with the heavy isotope are incubated with the affinity probe and free small molecule. The relative abundance of the captured protein is assessed based on the difference in signal intensity between the light- and heavy-isotope labeled proteins. In iTRAQ, proteins are labeled after trypsin digestion using isobaric tags to differentiate proteins from the active and inactive probe treatments.[32,33] The relative abundance of proteins is determined based on the ratio of the isobaric tags

between treatments. Protein identification has been facilitated by significant technological advancements in mass spectrometry and also in sample preparation prior to MS/MS analysis, which allows sensitive detection and enrichment of low abundance proteins.

Drug affinity responsive target stability (DARTS) is another mass spectrometry-based target protein identification method. DARTS represents an alternative method to chemical derivatization and probe design to elucidate the direct target of small molecules, while still interrogating the proteome.[34] DARTS utilizes the unmodified small molecule as the probe and is based on the decreased susceptibility of proteins to protease degradation upon binding of the small molecule. Resistance to protease degradation may be due to either stabilization of the target protein via ligand binding or the small molecule masking the protease recognition site.[34] DARTS has been utilized for several natural products of marine and terrestrial origins such as didemnin B, FK506, rapamycin and resveratrol.[34] The marine tunicate-derived didemnin B was utilized as a model compound to validate the utility of DARTS for target identification.[34] Jurkat cells were treated with 1 μg/mL didemnin B or solvent control. Whole cell lysates were subjected to thermolysin- or mock-digestion and subsequently profiled by SDS-PAGE and visualized by Coomasie Blue staining.[34] Significant enrichment of the protein band with molecular weight ~50 kDa was observed in didemnin B-treated cells and identification using MS indicated that the primary protein present at high abundance in didemnin B-treated cells was EF-1α, in accord with the observed direct target of this small molecule using chemical proteomics.[34] Despite the validation of DARTS for target identification of several small molecules, its full potential for target identification is yet to be realized.[34] The potential drawbacks of DARTS will be related to the binding affinity of the small molecule for its target and also the inherent variability in the susceptibility of proteins to proteolysis because of the conformational energy landscape.[34]

3 Mechanisms of Action and Direct Cellular Targets of Biologically Active Cyanobacterial Metabolites in Mammalian Cells

3.1 Classical Anticancer Drug Targets

Inhibition of microtubule and microfilament assembly is one of the well-represented mechanisms of action of antiproliferative natural products.[35] Apart from antimetabolites and topoisomerase poisons, tubulin-targeting agents from Nature were among the first small molecules to achieve approval for clinical use. In contrast, small molecules that act on actin have failed to gain clinical approval but have largely been used as pharmacological probes to study actin function. Actin- and tubulin-targeting agents are among the first compounds to have defined MOA. Tubulin-targeting agents were utilized as first-line drugs for cancer because of their ability to halt uncontrolled cell division by causing mitotic arrest that culminates in programmed cell death (Fig. 4).[36,37] This method

of curbing the growth of malignancies, while effective, may pose detrimental effects to normal cells since tubulin is also present in these cells. Both actin and tubulin are critical in maintaining cell shape, motility and cell division, and these proteins are largely abundant in cells, making the observation of their pharmacological modulation relatively easy by monitoring the tubulin or actin network and cellular morphology by microscopy.[38] The abundance and ease in monitoring of tubulin and actin may have posed as biases in the discovery of modulators of these proteins during the dawn of the development of anticancer agents.

Fig. 3

3.1.1 TUBULIN-TARGETING AGENTS

The discovery of tubulin-targeting agents continues to be an active research field because of the chemodiversity of active small molecules. Small molecules that disrupt microtubule proteins do not significantly change the microtubule mass, and rather, suppress the microtubule dynamics.[35] Tubulin poisons from cyanobacteria either bind to the Vinca domain or colchicine binding site, thereby acting in a comparable manner to the vinca alkaloids or colchicine, respectively.[35] Despite several tubulin-targeting agents gaining clinical approval, there are concerns on the use of these small molecules for chemotherapeutic intervention related to tumor specificity, undesired effects, most notably peripheral neuropathy and drug resistance evoked by increased expression of P-glycoprotein.[37] In addition to pursuing their tumor growth inhibitory activity, tubulin inhibitors are also being explored for their antivascular effects leading to inhibition of angiogenesis.[36]

Vinca domain binding agents. The modified linear peptides belonging to the dolastatin 10-type of compounds are among the predominant class of tubulin-targeting agents from marine cyanobacteria (Fig. 4).[39] Dolastatin 10 is characterized by a terminal dimethylated amino acid residue and several nonproteinogenic amino acids (Fig. 4).[40] Dolastatin 10 was initially isolated from the sea hare *Dolabella auricularia*, but the low yield and subsequent purification of the related compound symplostatin 1 from the cyanobacteria *Symploca hydnoides* indicated the dietary origins of dolastatin 10.[15,40–42] Symplostatin 1 and dolastatin 10 only differed in the N-terminal amino acid residue, with *N,N*-dimethyl Ile in the former and *N,N*-dimethyl Val in the latter (Fig. 4).[41] Dolastatin 10 was isolated as the antiproliferative component in *D. auricularia*, following large-scale purification, and was demonstrated to arrest the cells in metaphase.[39] Dolastatin 10 and symplostatin 1 both exhibited potent antiproliferative activity, with pico- to nanomolar IC_{50}s against a wide array of cancer cells.[39,43] Dolastatin 10 was shown to affect the polymerization of purified tubulin. Structural similarities between dolastatin 10 and the tubulin inhibitor phomopsin A suggested that dolastatin 10 may bind to the Vinca domain of tubulin, analogous to phomopsin A.[39] To probe this hypothesis, the binding of [³H]-labeled vincristine and [³H]-labeled

colchicine to tubulin was monitored in the presence of dolastatin 10.[39] Dolastatin 10 inhibited the binding of radiolabeled vincristine without any effect on radiolabeled colchicine. In addition to tubulin binding, dolastatin 10 was also shown to inhibit critical events during tubulin assembly such as tubulin-dependent GTP hydrolysis and nucleotide exchange on β-tubulin. To determine possible binding sites of dolastatin 10 on α- and β-tubulin, a combination of molecular dynamics simulation and molecular modeling studies was undertaken.[44] Despite the high homology between α- and β-tubulin, dolastatin 10 only demonstrated extensive molecular interactions with β-tubulin and occupied a binding pocket adjacent to the exchangeable GTP site that is composed of the amino acid residues: Ser172, Lys174, Val175, Asp177, Asn204, Glu205, Tyr208, Asp209, Phe212, Pro220 and Tyr222.[44] The binding pocket occupied by dolastatin 10 is the same as that for cryptophycins 1 and 52, hemiasterlin and phomopsin A.[44] This was corroborated by experimental observations that these structurally unrelated modified peptides competitively inhibit each other from binding to tubulin. The dolastatin 10 analog, symplostatin 1, also caused disruption of microtubule proteins. The effects of both compounds on cellular microtubules in A10 rat aortic smooth muscle cells were probed by indirect immunofluorescence using monoclonal β-tubulin antibody.[43] Both compounds caused almost complete loss of cellular microtubules at low nanomolar concentrations and the formation of abnormal mitotic spindles.[43]

Fig. 4

Due to its potent activity, dolastatin 10 was pursued for clinical trials for hormone refractory adenocarcinoma and recurring platinum-sensitive ovarian carcinoma. Further development of dolastatin 10 was discontinued, however, due to marginal efficacy and also peripheral neuropathy.[45] The preclinical studies on symplostatin 1 in two murine solid tumor models indicated a delay in tumor growth in response to treatment.[43] However, symplostatin 1 was poorly tolerated by test animals and also caused gastrointestinal and liver toxicity.[43] Dolastatin 10 was not pursued for clinical development, but it served as the template for the design of synthetic analogs that have reduced toxicity and were intended for targeted delivery. The dolastatin 10 analog, monomethyl auristatin E, served as the drug portion of the antibody-drug conjugate brentuximab vedotin, which was approved in 2011 for clinical use in Hodgkin's and systemic anaplastic large cell lymphoma (Fig. 1).[17,46] Brentuximab vedotin consists of the drug monomethyl auristatin E linked to a cathepsin B-cleavable linker and a CD30-targeting antibody.[17,46] This targeted approach allows for selective delivery of monomethyl auristatin E to tumor cells, which express higher levels of CD30 antigen and have low cross-reactivity in normal cells. Four molecules of monomethyl auristatin E are attached to cAC10 interchain Cys residues.[17] Through receptor-mediated endocytosis, the antibody-drug conjugate is taken up by the cell and by the proteolytic action of

lysosomal enzymes such as cathepsins, the free drug is released.[17]

Several other modified linear peptides (Fig. 4) belonging to the dolastatin 10-type of compound class were purified from marine cyanobacteria, such as symplostatins 3 and 4[47,48], malevamide D[49] and belamide A.[50] These compounds showed varying antiproliferative activity and, consequently, tubulin disrupting effects. The dolastatin 10/15 hybrid, symplostatin 4, exhibited moderate antiproliferative effects with IC_{50} values of 12 and 53 µM against HeLa and HT29 cells.[48] The low potency of symplostatin 4 can be attributed to several structural modifications in both N-terminal and C-terminal regions of symplostatin 4, relative to dolastatins 10 and 15.[48]

Cryptophycins (Fig. 4) are a class of cyanobacterial depsipeptides distinguished by a modified octenoic acid moiety with a distinctive 7,8-epoxy-8-phenyl terminus.[51] To date, more than 25 members of this compound class have been purified from *Nostoc* spp.[52] The major metabolite, cryptophycin-1, showed potent antifungal activity against *Cryptococcus* but not *Candida*.[51,53] An analog of cryptophycin-1, cryptophycin-24 or arenastatin A (Fig. 4) was isolated as the bioactive component of the marine sponge *Dysidea arenaria*. This highlighted the close association between the source sponge and a cyanobacterial symbiont in the production of secondary metabolites.[54]

Initial toxicity assessment in mice indicated that cryptophycin-1 is a potent, toxic compound with TD_{50} of 6.25 mg/kg.[53] Subsequent studies on cryptophycin-1 indicated that it is indeed a potent cytotoxic agent, equipotent in drug sensitive and resistant cell lines, with subnanomolar IC_{50}s.[55] Indirect immunofluorescence studies using A10 vascular smooth muscle cells indicated significant depletion of cellular microtubules and reorganization in vimentin filaments, without any effect on cytoskeletal components.[55] The effect of cryptophycin-1 on *in vitro* tubulin polymerization was extensively studied by several groups. Among the known tubulin poisons, the MOA of cryptophycin-1 closely resembles that of vinblastine, acting as a microtubule disrupting agent. Cryptophycin-1 is a noncompetitive inhibitor of [³H]vinblastine with K_i of 3.9 µM, while it is a competitive inhibitor of [³H]dolastatin 10 with K_i of 2.1 µM, indicating that cryptophycin-1 occupies the peptide binding site of the vinca domain of tubulin. The interaction of arenastatin A with porcine brain tubulin was likewise probed using [³H]arenastatin A.[56] Binding experiments indicated that there is one binding site for arenastatin A per tubulin heterodimer, and the tubulin poisons rhizoxin was a competitive inhibitor while vinblastine partially competed with arenastatin A.[56]

The potent activity of the natural cryptophycins served as the basis for the design of more potent analogs to pursue for further development. Among these, cryptophycin-52 is regarded as the most potent inhibitor of microtubule dynamics (requiring only 5-6 molecules to sufficiently decrease microtubule dynamicity by 50%) which has a high affinity with tubulin and dissociates slowly, with K_d of 47 nM.[57] Cryptophycin-52 (LY355703) reached Phase II clinical trials for non-small cell lung

carcinoma (NSCLC) and ovarian cancer previously treated with platinum-based drugs.[58,59] Poor response and unacceptable toxicity was seen in NSCLC patients, while better prognosis was observed in ovarian cancer. This indicated that the dose and schedule of cryptophycin-52 treatment is crucial for activity and in minimizing undesired side effects.[58,59]

Colchicine domain binding agents. From a bioassay-guided purification, the antiproliferative compound curacin A (Fig. 4) was obtained as the active principle.[60] Curacin A is a unique fatty acid that is modified by a terminal thiazoline-methyl-cyclopropane moiety.[60] Evaluation of its differential cytotoxicity profile in the NCI-60 screen followed by COMPARE analysis indicated similarity with anti-tubulin agents and, hence, suggested microtubule proteins as the molecular target of curacin A.[60] Like other tubulin targeting agents, curacin A also caused G2/M cell cycle arrest. Assessment of the effects of curacin A on purified tubulin corroborated its inhibitory activity on tubulin polymerization. Curacin A competed with radiolabeled colchicine for binding to tubulin, but not with vinblastine, thus suggesting that curacin A occupies the colchicine binding site, distinct from tubulin-targeting cyanobacterial peptides.[61] Radiolabeled curacin A was prepared through biosynthesis using $Na[^{14}C]$acetate as precursor and used to probe the interactions of curacin A with tubulin.[61] Binding studies using $[^{14}C]$curacin A indicated rapid association with tubulin, with k_f 4.4 x 10^3 $M^{-1}s^{-1}$.[61] Dissociation from tubulin is very slow with a half-life of 50–70 h at 32°C. However, this was not due to formation of a curacin-tubulin covalent adduct, as $[^{14}C]$curacin A is released from tubulin following urea treatment. Scatchard analysis indicated significant superstoichiometric amounts of $[^{14}C]$curacin A bound to tubulin and suggested the presence of two binding sites for curacin A in tubulin.[61] The binding of curacin A to tubulin resembles that of combrestatin A-4 and podophyllotoxin, while its dissociation from tubulin is similar to the behavior of colchicine.

3.1.2 ACTIN-TARGETING AGENTS

The ability of actin to control cytokinesis (the separation of two daughter cells) made it a logical target in cancer chemotheraphy.[62] While actin targeting agents have yet to gain approval for clinical use, these small molecules are perhaps among the most prevalent molecular probes to study actin function. The fungi-derived compound cytochalasin was initially used to define the functions of actin in maintaining cell shape and cellular motion.[63] In addition, the visualization of microfilament assembly is commonly accomplished using a fluorescent derivative of the natural product phalloidin.[63]

Fig. 5

The family of antiproliferative cyclodepsipeptides belonging to the dolastatin 11-class (Fig. 5) was purified from both cyanobacteria and *D. auricularia*.[64] The compounds are different from dolastatins 10 and 15 since this family of compounds did not induce mitotic arrest or any interaction with tubulin or microtubule proteins. Instead, dolastatin 11 caused a rapid change in cell shape, characterized by extensive retraction of the cytoplasm, leading to the formation of binucleated cells.[65] These morphological changes indicated that dolastatin 11 potentially interacted with the cytoskeletal protein actin. The antiproliferative activity of dolastatin 11 against PtK1 cells was compared with the known actin-targeting agents jasplakinolide

and latrunculin B. Dolastatin 11 showed better biological activity and was close to 3- and 12-fold more potent than jasplakinolide and latrunculin B, respectively.[65] PtK1 cells were incubated with jasplakinolide, dolastatin 11 or solvent control at varying durations, using IC_{50} and $10\times$ IC_{50} concentrations, and the effects on microfilaments of PtK1 cells were evaluated by immunofluorescence detection using FITC-labeled anti-actin antibody. Cytoplasmic retraction was not observed at lower concentrations for both compounds for all time points, and little difference was observed in the cellular effects of the two compounds. At higher concentrations, dolastatin 11 and jasplakinolide showed significant differences in the rate of inducing their cellular effects. Dolastatin 11 caused few stress fibers to remain after 30 min, and microfilaments were no longer observable at later time points. The effects of dolastatin 11 on the assembly of purified actin were evaluated using pyrenyl-labeled actin.[65] Incorporation of pyrenyl-labeled actin on growing unmodified actin leads to an enhancement in fluorescence that can be readily monitored. In the presence of inducing salts (50 mM KCl, 2 mM $MgCl_2$, 1 mM ATP) and 10 µM actin/pyrenyl-labeled actin, dolastatin 11 stimulated actin polymerization, with no significant difference to the effects of jasplakinolide or phalloidin.[65] Further comparison of the effects of these three compounds on actin polymerization was done in the absence of inducing salts in the polymerization reaction. Dramatic differences in the activities of dolastatin 11, jasplakinolide and phalloidin were observed; the actin stimulatory activity paralleled the observed cytotoxicity for these compounds, with dolastatin 11 being the most potent.[65] Further differences between dolastatin 11 and jasplakinolide were observed for the inhibition of binding of FITC-labeled phalloidin to actin polymer. Dolastatin 11, unlike jasplakinolide, was not able to displace FITC-labeled phalloidin from actin polymer, and suggested that dolastatin 11 occupies a distinct binding site.[65] The binding of dolastatin 11 to actin was examined using X-ray diffraction diagrams that were derived from oriented filament sols.[66] The results corroborated the biochemical analysis, wherein dolastatin 11 did not compete with phalloidin, evident from the different binding sites occupied by these two natural products in the same region of the F-actin strand. Both dolastatin 11 and phalloidin occupy opposite sides of the gap between two long-pitch F-actin strands.[66] This indicated that modulation of the interaction between F-actin strands is a key aspect in controlling microfilament assembly. Several analogs of dolastatin 11 were also purified from marine cyanobacteria such as majusculamide C[67] and lyngbyastatins 1 and 3.[68,69] These compounds were shown to induce similar morphological effects on cells, which thus indicated effects on actin polymerization as well.

Lyngbyabellins[70–73] and hectochlorin[74] (Fig. 5) are structurally related modified cyclodepsipeptides characterized by a bis-thiazole moiety and an unusual dichlorinated β-hydroxy acid. These compounds exhibited moderate antiproliferative activity, with low-micromolar IC_{50}s against a variety of cell lines.[70] Initial evidence for the effects of this class of compounds on actin came from morphological changes in treated cells, characterized by an extensively retracted cytoplasm and binucleated cells, concurrent with a disrupted microfilament network.[70] The assembly of purified actin in the presence of hectochlorin was also monitored using light scattering experiments.[74] Hectochlorin showed a dose-dependent effect in promoting actin polymerization, comparable to jasplakinolide.[74] However, hectochlorin did not displace the binding of FITC-labeled phalloidin to actin polymer, indicating a distinct

binding site from phalloidin.[74] The MOA and target of the lyngbyabellin-class of compound were validated after it was purified as the bioactive component in a targeted screening for new actin modulators using high content image analysis.[75] In this screening for actin-targeting compounds, the documented changes in the morphology of cancer cells following compound treatment were utilized as indicators of activity.[75] HeLa cells treated with actin-targeting compounds showed decreased cytoplasmic area of up to 70% and an increase in distance between the centroid of the nucleus and centroid of the entire cell.[75] Plotting the distance between centroids of nucleus and cell versus the area of the cytoplasm allowed for clustering of actin stabilizing and destabilizing compounds. Nuclear protrusion arising from actin-disruption by small molecules was first observed for the cyanobacterial compound tolytoxin.[76] On this basis, the purified lyngbyabellin C was shown to be an actin stabilizer, and the cellular effects of lyngbyabellin C were accounted for by its weak inhibition of the polymerization of purified F-actin.[75] This cell morphology-based screening also identified seven known actin targeting compounds: cytochalasin D, doliculide, jasplakinolide, latrunculin A, mycalolide B, seragamide A and swinholide, from a library of 400 purified natural products and, thereby, validated this screening platform.[75] In addition, the cyanobacteria-derived compound bisebromoamide (Fig. 5) was also identified as a hit compound; likely an actin stabilizer.[75] The morphological assay was validated by monitoring the assembly of purified actin in the presence of varying concentration of bisebromoamide. A concentration dependent effect on actin polymerization of pyrene labeled G-actin was observed with bisebromoamide treatment, together with inhibition of F-actin depolymerization.[75] Synthesis of a bisebromoamide-fluorescein conjugate and monitoring of cellular localization in HeLa cells demonstrated the localization of bisebromoamide on actin filament.[75]

3.2 Nonclassical Anticancer Drug Targets

The advent of advanced molecular biology tools and the omics era has led not only to improved identification of cellular targets of small molecules but also in defining deregulated components of signaling pathways in cancer. It has become apparent that cancer cells are able to achieve their hallmark characteristics by mutations of proto-oncogenes to oncogenes leading to either increased expression or constitutively active signaling molecules such as enzymes, transcription factors, and cell surface receptors.[77,78] As such, the inhibition of these overactive or upregulated enzymes has been recognized as a promising strategy for mitigating tumor growth. The differential expression of selected oncogenes in cancer compared to normal cells also allowed for the development of either selective small molecules or the design of magic bullets aimed at cancer cells, thereby giving improved success of the therapy and management of potential side effects. In addition, the loss-of-function of tumor suppressor genes is key to progression of malignancies, and reactivation of the expression of these genes has been recognized as bona fide targets for cancer therapy.[77,78] Hence, the design of effective small molecule therapeutics for cancer that has distinct mechanisms of action from classical agents can also be associated with the improved understanding of the molecular basis of the disease. Several small molecules from cyanobacteria (Fig. 6) have been demonstrated to act via novel mechanisms and on different targets compared with classical anticancer agents.

Fig. 6

3.2.1 SECRETORY PATHWAY

The apratoxins (Fig. 6) are a group of cyclodepsipeptides notably recognized by the presence of a contiguous pentapeptide chain, a modified Cys residue and a highly functionalized polyketide chain.[79–84] The first member of this group of compounds, apratoxin A, showed potent *in vitro* antiproliferative activity against cancer cells.[79] Apratoxin A did not affect the classical anticancer drug targets such as microfilaments, microtubules and topoisomerases, with the NCI-60 screening and COMPARE profile of apratoxin A indicating a novel MOA.[79] Transcriptome analysis of HT29 cells treated with apratoxin A indicated changes in mRNA levels for more than 100 genes which include oncogenes, tumor suppressors, components of the cell cycle and stress response regulators.[85] Genes that confer resistance to apratoxin A when overexpressed were interrogated using a library of 27,000 cDNA transiently transfected in U2OS cells. This genome-wide screening identified 46 cDNAs that attenuated the cytotoxic effects of apratoxin A through anti-apoptotic mechanisms, blockade of apratoxin A-dependent G1 cell cycle arrest and induction of apratoxin A-independent cell cycle arrest.[85] A significant portion of the cDNAs conferring resistance to apratoxin A encoded for fibroblast growth factor receptor (FGFR) variants, some of which also have higher transcript levels in NCI-60 cell lines that were less susceptible to apratoxin A.[85] Quantitative proteomics using iTRAQ labeling indicated that apratoxin A modulated the levels of a subset of proteins, specifically receptors or membrane-associated proteins and proteins that are localized in the endoplasmic reticulum.[86] In addition, immunoblot analysis demonstrated that apratoxin A downregulated the levels of several cancer-associated receptors such as c-Met, Her2, PDGFR-β, and IGF1R-β.[86] To elucidate the mechanism of apratoxin A-mediated downregulation of receptors, *in vitro* translation with or without microsomal membrane with [^{35}S]methionine incorporation was performed and monitored by SDS-PAGE followed by autoradiography. Apratoxin A did not affect protein synthesis but rather inhibited glycosylation and also signal peptide-cleavage by preventing cotranslational translocation of proteins bound for the secretory pathway.[86] Non-functional non-translocated receptors underwent proteasomal degradation instead. In a parallel study, apratoxin A-induced downregulation of membrane receptors was also suggested to occur as a result of demonstrated binding of an oxazoline analog of apratoxin A to HSP70, which in turn could promote HSP90 client protein (including receptor) degradation.[87] The ability of apratoxin A to inhibit cotranslational translocation suggested the simultaneous downregulation of membrane receptors and inhibition of secretion of growth factors and other ligands.

Downregulation of receptor expression and secretion of corresponding ligands by apratoxin A proved to be a promising strategy to attenuate *in vivo* tumor growth in a murine colorectal tumor xenograft model. However, significant toxicity was observed with apratoxin A treatment and found to be irreversible.[88] The design of new analogs of apratoxin A was then aimed to obtain maximum *in vivo* potency but without the irreversible toxicity exerted by apratoxin A. The knowledge of the MOA of apratoxin A was utilized in the design of new analogs. Comprehensive SAR information was obtained with monitoring of the antiproliferative activities against cancer cells and the levels of VEGF-A and c-MET.[88] This corroborated that

the biological activities of the apratoxin class of compounds are intricately related to their ability to reduce the expression of receptors and ligands which are crucial aspects in several of the clinical hallmarks of cancer. Importantly, *in vivo* studies suggested that the modified Cys unit is responsible for the irreversible toxicity of apratoxin A, indicating that this problem was a result of off-target activity rather than mechanism-based.[88] The second generation apratoxin analog, apratoxin S4, showed the same effects as apratoxin A in cotranslational translocation, with potent *in vivo* activity in a colorectal xenograft model, but did not show irreversible toxicity.[88] The ability to segregate the off-target effects and relevant pharmacological actions of apratoxin A through selective modifications on the core structure allows these potent small molecules to be further developed. Further structural modifications have led to an analog that is less prone to chemical and metabolic deactivation (apratoxin S8) and an even more potent analog (apratoxin S9).[89]

3.2.2 HISTONE DEACETYLASES

Histone deacetylases (HDACs), enzymes that modulate the acetylation of histones and nonhistone proteins, are divided into two groups, the canonical HDACs (classes I, II, IV) and class III sirtuins.[90] Canonical HDACs utilize a catalytic Zn^{2+} residue and a His-Asp dyad system for the deacetylation reaction.[90] On the other hand, sirtuins are NAD^+-dependent enzymes, which have weak deacetylase activity and act mainly as ADP-ribosyltransferase.[91] Modulation of histone acetylation neutralizes interactions between histone proteins and DNA of nucleosomes, thereby affecting higher-order chromatin structure and favoring the binding of transcription factors, ultimately leading to gene expression changes (Fig. 7).[92] In addition, recent studies identified many non-histone proteins that are also subjected to acetylation and are likely to be substrates of canonical HDACs and SIRTs as well.[10,93] Because of the well-documented cellular consequences of modulation of histone acetylation, pharmacological intervention targeting HDACs is being extensively explored for drug development.[94] Two HDAC inhibitors have been approved for clinical use; the natural product romidepsin (FK228)[95,96] and one natural product-like compound, vorinostat (SAHA).[97] Combination therapy and non-cancer applications are also being pursued for HDAC inhibitors in the preclinical and clinical trial stages.[93] The major challenge in HDAC inhibitor development is finding isoform-selective agents with the hope of minimizing undesired side effects of HDAC inhibitors and also defining the physiological roles of different HDAC isoforms.[93]

Fig. 7

While several canonical HDAC inhibitors have been purified from terrestrial microbes such as trichostatins, FK228 and trapoxins, HDAC inhibition is so far a minor theme in marine microbes and macroorganisms.[93] The sponge-derived psammaplin A,[98] marine fungus-derived microsporins[99], and the cyanobacterial compounds largazole[100,101] and santacruzamate A[102] are the only known marine-sourced canonical HDAC inhibitors.

Largazole (Fig. 6) was purified from a *Symploca* sp. collection from Key Largo, Florida using a bioactivity-directed approach.[101] The MOA of largazole is disguised by its prodrug characteristics, where activation by protein-assisted hydrolysis is required to liberate the bioactive species largazole thiol.[103,104] Largazole thiol features a 3-hydroxy-7-mercaptohept-4-enoic acid moiety, a characteristic structural feature of the cyclic

depsipeptides FK228, FR-901375,[105] and spiruchostatins.[106,107] This moiety is also disguised in FK228, FR-901375 and spiruchostatins as a disulfide, which requires glutathione-assisted reduction to liberate the bioactive species.[95] FK228 was first shown to inhibit HDACs by similarity of its phenotypic effect with the known HDAC inhibitor trichostatin A in a screen for activators of SV40 promoter-dependent transcription.[108] The structural similarity of the "warhead moiety" of largazole thiol and FK228 then indicated a similar direct target and MOA.[103,104] Largazole was shown to selectivity inhibit class I HDACs, with comprehensive assessment of inhibitory activity against 12 purified human HDACs using fluorogenic HDAC substrates.[100] The isoform selectivity of largazole is consistent with the cyclic depsipeptide HDAC inhibitor FK228, with largazole exhibiting slightly better potency.[100] The molecular target of largazole was also confirmed by SAR studies that indicated the importance of the 3-hydroxy-7-mercaptohept-4-enoic acid moiety for biological activity.[109] Molecular interactions of largazole with its target protein were also elegantly demonstrated by X-ray cocrystallization with HDAC8 at 2.14 Å resolution.[110] Largazole binds to the HDAC active site and coordinates the active site Zn^{2+} residue of HDAC8, via the thiol moiety, present as thiolate and the macrocycle occupying the rim of the active site.[110] Visualization of the molecular interactions of largazole with HDAC8 is the first ever reported for a cyclic depsipeptide HDAC inhibitor and, hence, provided critical insights into the binding modes of related compounds and will be valuable in the design of next generation HDAC inhibitors, thereby serving as an important molecular probe.[110]

The effects of the HDAC inhibitors largazole, FK228 and SAHA on the transcriptome was assessed using comparative microarray analysis of HCT116 cells treated with these compounds, leading to significant changes in gene expression of >800 genes.[111] For example, these HDAC inhibitors significantly upregulated the expression of cell cycle inhibitor proteins p21, p19, p57 and p15 and a proapoptotic BCL2 protein variant (BCL2L11), and at the same time downregulated the levels of growth factor receptors (EGFR, HER2, MET) and also CDK6 and cyclin D1.[111] In addition to its antiproliferative properties *in vitro* and *in vivo*, largazole also modulated the invasiveness of breast cancer cells through gene expression changes and non-histone mediated effects.[112] Largazole was able to reverse the epigenetic silencing of E-cadherin expression in invasive breast cancer cells and to modify the composition of the E-cadherin complex.[112] Largazole was shown to strongly induce E-cadherin expression (histone-mediated) and also increased the association of E-cadherin with γ-catenin to ensure proper cell membrane localization (non-histone mediated).[112] These effects of largazole were a direct consequence of HDAC inhibition as trichostatin A and SAHA also displayed the same cellular effects, although largazole was more effective.[112] Largazole's anti-invasive properties were enhanced in combination with dexamethasone which blocked the production of the pro-invasive cleaved form of CDCP1 (CUB domain-containing protein 1), present in the E-cadherin complex, through upregulation of plasminogen activator inhibitor-1.[112] Largazole and dexamethasone cooperated to induce E-cadherin localization in the plasma membrane.[112]

Combination therapy is also an active area of interest for HDAC inhibition. Another approach to design combination therapy is through exploring the combinatorial pharmacology utilized by marine cyanobacteria.[48] In this regard, a

combination of largazole and symplostatin 4 was employed to achieve cooperative effects in preventing the proliferation of human colorectal adenocarcinoma cells.[48] It has been proposed that HDAC inhibitors sensitize cancer cells to the proapoptotic effects of microtubule disruptors and other agents.[93]

While largazole was initially purified based on its antiproliferative effects, the application of this small molecule has been expanded. Non-cancer therapeutic applications for HDAC inhibitors are also being actively explored. In the case of largazole, it was shown to also have bone-forming properties[113] and cytoprotective effects against liver fibrosis.[114] The *in vivo* osteogenic activity of largazole was attributed to its ability to stimulate bone formation and suppress bone resorption.[113] These effects were mediated in part by largazole's ability to modulate the expression of ALP, OPN and BMP-2, 4, 6, 7, and 9.[113] The selectivity of the antiproliferative effects of largazole for transformed cells served as an advantage, as largazole did not exhibit any cytotoxic effects against murine pluripotent mesenchymal precursor C2C12 cells.[114] The selective action of largazole was also observed in hepatic cells, where largazole increased the acetylation of histone H3 and H4 and also inhibited the proliferation of hepatic stellate cells, leading to reduction of liver fibrosis.[114] The effects of largazole were shown to be a direct consequence of histone acetylation as a decrease in biological activity was observed with siRNA-mediated knockdown of HDACs 1–3. Downstream effects of HDAC inhibition in hepatic stellate cells include changes in expression of TGFβR2, VEGF, VEGFR, Smad2 and phosphorylated Akt.[114] Efforts are underway to modulate the pharmacokinetics and pharmacodynamics of the natural product by designing largazole-based HDAC inhibitors with altered of prodrug properties.[115] Furthermore, the class I HDAC selective largazole scaffold now serves as a template for the synthesis of isoform specific inhibitors.[116]

It must be noted, however, that HDAC inhibitors can oftentimes appear as promiscuous hits in screening, due to their ability to modulate gene expression. For example, psammaplin A was identified as a modulator of the Wnt signaling pathway.[117] Rather than acting on the signaling pathway itself, the activity of psammaplin A was due to significant transcriptional activity.[117] This was observed in the case of largazole in the screening of inhibitors for ubiquitin activating enzyme (E1) using mink lung epithelial cell line (Kip16) stably expressing the N-terminal GFP-p27 fusion.[118] Largazole showed nanomolar potency for GFP-p27 stabilization, however, E1 inhibition was observed at high micromolar concentration.[118]

Another HDAC inhibitor recently purified from a *Symploca*-like marine cyanobacterium is santacruzamate A (Fig. 6), structurally reminiscent of the pan-selective HDAC inhibitor SAHA.[102] This compound, while showing striking structural similarity with SAHA, was determined to be a class I selective HDAC inhibitor with potent activity at the sub-nanomolar range against HDACs 2,4 and 6.[102] The HDAC inhibitory profile of santacruzamate A showed selectivity for certain class I over the tested class II HDACs.[102] The antiproliferative activity of santacruzamate A is only modest with low-micromolar GI_{50}s against HCT116 and HuT-78 cells and, depending on the cell type, showed 2–10-fold difference in activity compared to SAHA.[102] The potent and selective inhibitory activity of santacruzamate A in cell-free systems provides a unique opportunity to explore the molecular determinants of selectivity in hydroxamate-type HDAC

inhibitors which have been known to be pan-selective inhibitors.

While the pharmacophore for inhibitors of canonical HDACs and their cellular effects have been clearly established, these areas are less explored for sirtuins.[93] The majority of sirtuin modulators have been derived from plants and agents targeting these proteins from marine sources have not been prevalent.[119] From marine cyanobacteria, tanikolide dimer is the only SIRT inhibitor isolated to date.[120] This compound was purified using target-based screening for SIRT2 inhibitors.[120] Tanikolide dimer showed varying IC_{50}s against SIRT2, from sub-nanomolar to low-micromolar, depending on the assay protocol employed.[120] The activity of tanikolide dimer in the enzymatic assay, however, did not translate to potent inhibition of the growth of the human lung H-460 cancer cell line, consistent with other SIRT2 inhibitors. Thus, this SIRT inhibitor may find utility as a pharmacological probe and in non-malignant applications.[120]

3.2.3 PROTEASOME

The ubiquitin-proteasome pathway is one of the key mechanisms to regulate protein levels. Proteins tagged by polyubiquitination are subjected to proteolytic degradation by the proteasome.[121] The 26S proteasome consists of a 20S proteolytic core and a 19S regulatory particle.[121] The 20S proteolytic core is critical to degradation of protein substrates, containing two chymotrypsin-like, two trypsin-like and two caspase-like sites, while the 19S regulatory protein is responsible for substrate recognition and priming for proteolysis.[121] The role of the proteasome in cancer was suggested by the high activity in rapidly dividing cells and the increased cell death associated with proteasome inhibition. The validation of the proteasome as a promising target for cancer therapy was fully realized with the approval of bortezomib for multiple myeloma.[121, 122]

^{1}H NMR- and bioactivity-guided purification of a *Symploca* collection yielded two potent antiproliferative agents, carmaphycins A and B (Fig. 6).[123] These compounds are characterized by a tripeptide moiety fused to a hexanoic acid and α,β-epoxyketone on the N- and C-terminal ends, respectively. Insights into the MOA of the modified peptides carmaphycins A and B were obtained from the structural similarity of these compounds with the epoxomicin class of compounds.[123] Carmaphycins and epoxomicins are characterized by an α,β-epoxyketone that has been demonstrated to be one of the key features in the latter for inhibiting the proteasome, forming a covalent bond with the catalytic Thr residue of the β5 subunit.[121] Carmaphycins inhibited the chymotrypsin-like (β5 subunit) activity of the 20S proteasome, with comparable potency to epoxomicin, culminating in potent inhibition of the growth of cancer cells, particularly those which harbor KRAS/tp53 mutations.[123] Using the X-ray crystal structure of the 20S proteasome derived from the complex with epoxomicins, the molecular interactions of carmaphycins were modeled.[123] Extensive hydrogen bonding, van der Waals and solvent interactions were observed. This molecular dynamics simulation also provided insight into the role of the distinctive sulfoxide or sulfone moieties in carmaphycins, derived from the Met residue. This moiety appears to contribute to additional hydrogen bonding interactions with Gly23 residue of the 20S proteasome.[123]

There is much promise on the proteasome as a target of anticancer drugs, with the recent approval of the proteasome inhibitor, carfilzomib, for multiple myeloma.[124] Carfilzomib was designed based on the natural product epoxomicin and

highlights the importance of knowledge of the drug target to effectively design second-generation agents that are potent with good solubility and pharmacokinetic properties.[124] The proteasome serves as an attractive target not just for cancer but other diseases as well, such as lupus nephritis, inflammation, reperfusion injury after stroke, infection and stimulation of bone and hair growth.[121]

3.2.4 PROHIBITIN

Aurilides[125–127] (Fig. 6) and related compounds lagunamides,[128–130] and kulokekahilides[131,132] are potent antiproliferative agents that have nanomolar IC_{50}s. Evaluation of aurilide B using the NCI-60 screening indicated potent antiproliferative activity with mean GI_{50} of 10 nM.[126] Information about the direct target and MOA of this compound class was derived from chemical proteomics using an aurilide affinity probe.[133] Aurilide was conjugated to a protease-cleavable polyproline linker with a biotin molecule tag and immobilized on neutravidin-agarose beads.[133] Significantly enriched protein was observed in the membrane fraction and subsequent MS/MS analysis indicated this to be prohibitin 1 (PHB1).[133] The results were also compared to a control probe, using the inactive analogue 6-*epi*-aurilide, which showed a decreased intensity of the protein band corresponding to PHB1.[133] To validate the results of affinity purification, the response of HeLa cells to aurilide treatment was probed for both PHB1 overexpression and depletion. Stable cell lines that overexpressed PHB1 showed resistance to aurilide, while siRNA-mediated partial knockdown of PHB1 led to sensitivity.[133] Comparison of the morphological changes in the mitochondria of *PHB1* knockdown and aurilide-mediated PHB1 inhibition yielded the same phenotype, with the mitochondria appearing as fragmented.[133] Immunoblotting experiments further demonstrated that PHB1 inhibition by aurilide A facilitates the proteolytic processing of the optic atrophy 1 (OPA1) protein, which in turn signals the initiation of apoptosis.[133] Aurilide represents the first small molecule inhibitor of PHB1 and thus serves as an important pharmacological probe in elucidating the role of PHB1 and OPA1 in the initiation of apoptosis.[133] In this case, the natural product aurilide enabled the discovery of a potentially novel anticancer drug target and also of a probe to understand the function of prohibitin and OPA1 in cancer progression.

3.2.5 KINASES

Several of the clinical hallmarks of cancer are products of deregulated kinase activity, either due to constitutive activity or upregulated expression.[134] The phosphorylation of substrate proteins by kinases plays a key role in activation or protein inhibition as well as in nuclear translocation that culminates in gene expression.[135] Kinases have been shown to act as oncogenes, or downstream effectors of transforming oncogenes and initiators of angiogenesis and metastasis.[136] Among the cancer-associated kinases are the fusion protein Bcr-Abl, epidermal growth factor receptor (EGFR), vascular epidermal growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).[134,136] The many kinases and their involvement in critical signaling pathways have made them critical drug targets for cancers, immunological, neurological, metabolic and infectious diseases.[136]

Bisebromoamide and scytonemin are two cyanobacteria-derived compounds shown to target kinases and related enzymes. Bisebromoamide is a potent antiproliferative agent that bears unique structural features such as pivalic acid, methylthiazoline, and an unprecedented 2-(1-oxopropyl)pyrrolidine moieties.[137] Bisebromoamide inhibited

PDGF-initiated signaling in NRK cells and attenuated the phosphorylation of ERK.[137] In addition to its effect on certain kinases, bisebromoamide was obtained as a screening hit for actin-targeting agents using high-content analysis for morphological changes in HeLa cells as a consequence of actin disruption.[75] However, the relationship between the kinase inhibitory activity and actin destabilizing effects of bisebromoamide to the potent *in vitro* antiproliferative activity is not fully elucidated. The structural basis for bisebromoamide-mediated kinase inhibition has not been characterized.

A target-based screen for inhibitors of polo-like kinase 1 yielded the cyanobacterial pigment scytonemin.[138] Polo-like kinase 1 has been demonstrated to have high expression in human tumors and is also an attractive drug target due to its involvement in cell cycle events such as mitosis, centrosome maturation, assembly of the bipolar spindle, separation of sister chromatids and exit from mitosis.[139] Based on binding studies, scytonemin acts as both competitive and noncompetitive inhibitor of polo-like kinase 1. The inhibition of PLK1 through pharmacological modulation by a small molecule has proven to be an effective anticancer strategy as seen for the small molecule BI-2536.[139]

Additional profiling of scytonemin showed inhibitory effects on other kinases such as Myt1, checkpoint kinase 1, cyclin-dependent kinase 1/cyclin B and protein kinase Cβ2.[138] As expected from the effects of scytonemin on kinases, the compound inhibited the proliferation of cells stimulated with growth factors, induced apoptosis but did not arrest cells at a specific stage, which may indicate multiple cellular targets for scytonemin, warranting further investigations.[138]

3.2.6 METAL CHELATION

Metal chelation is a possible mechanism of antiproliferative activity. Chelation of copper in particular has been actively explored for modulating angiogenesis. The copper chelating compounds penicillamine and tetrathiomolybdate have been evaluated in pre-clinical and clinical trials for anti-cancer and antiangiogenic activities.[140,141] Critical in exploiting copper chelation as an antiangiogenic therapy is maintaining a low level of copper to block angiogenesis and simultaneously obtaining sufficient amount for critical copper-dependent processes to prevent clinical toxicity.[142]

Fig. 8

Grassypeptolides are a group of bis-thiazoline containing cyclic depsipeptides (Fig. 8) with antiproliferative activity against a variety of cancer cell lines, with sub-nanomolar to low-micromolar IC_{50}s.[143,144] Related to the grassypeptolides are the marine invertebrate-derived compounds patellamides A and C, ascidiacyclamide and lissoclinamide. Their antiproliferative activities were previously demonstrated to be due to the metal chelating properties, binding Cu^{2+} and Zn^{2+} via the tandem thiazole/oxazole or thiazoline/oxazoline moieties.[145,146] In accord, the metal chelating activity of grassypeptolide A was assessed using mass spectrometry and circular dichroism (CD) measurements.[144] Addition of 1 eq of Cu^{2+} caused changes in the CD spectrum of grassypeptolide A, and the $[M-H+Cu]^+$ pseudomolecular ion was observed.[144] No additional change was observed at higher equivalence ratios. Addition of 1 eq of Zn^{2+} caused a slight positive change in the CD spectrum of grassypeptolide A, similar to effects of lissoclinamide 10.[144] Pseudomolecular ions corresponding to the Zn^{2+} adducts of grassypeptolide A were also observed. The contribution of

metal binding to the antiproliferative properties of grassypeptolide has not been demonstrated and other pleiotropic effects have also been suggested to possibly play a role. SAR studies indicated the importance of the bis-thiazoline moiety of grassypeptolides.[147] Weak antiproliferative activity (IC$_{50}$ in the high-micromolar range), was observed for grassypeptolide A analogs lacking the bis-thiazoline moiety.[147] Grassypeptolide A was also shown to cause accumulation of cells at G0-G1 and apoptosis.[147] An increased expression of the cell cycle inhibitor proteins p27 and p21 proteins was observed, with concomitant decrease in expression of antiapoptotic BCL-2 and BCL-xL.[147] In addition, grassypeptolide A was also demonstrated to be a selective inhibitor of dipeptidyl peptidase 8 (DPP8), potentially linked to the observed cellular effects of lower IL-2 production and proliferation of activated T cells.[148] This additional bioactivity indicates the potential of grassypeptolide as a probe to elucidate the functions of DPP8, a type of serine protease.[148]

3.3 Protease Inhibition

3.3.1 SERINE PROTEASES

Serine protease inhibition is a major mechanistic theme, with more than 100 members in this type of compounds sourced from terrestrial, freshwater and marine cyanobacteria.[19,52] The DPP8 inhibition by grassypeptolides[148] is rather unique among cyanobacterial compounds. Most of these serine protease inhibitors are cyclic depsipeptides bearing the modified glutamic acid residue, 3-amino-6-hydroxypiperidone (Ahp) (Fig 8). They act as competitive inhibitors that mimic the endogenous substrates of serine proteases, but are not hydrolytically cleaved (Fig. 8).

The X-ray cocrystal structures of serine proteases were derived with compounds mostly from terrestrial cyanobacteria. The scyptolin-porcine pancreatic elastase,[149] lyngbyastatin 7-porcine pancreatic elastase[150] and A90720A-porcine pancreatic trypsin[151] complexes provided insights into the molecular determinants of selectivity and potency, and corroborated with enzymatic assay results. The Ahp moiety and the adjacent residue on the N-terminal side are central to the biological activity, with the latter occupying the enzyme active site. The residue on the N-terminal side of Ahp determines specificity; the presence of a basic residue (e.g., Arg in A90720A) provides selectivity for inhibiting trypsin, while a hydrophobic residue at this position (e.g., Phe in micropeptin T-20) gives preferential inhibition for chymotrypsin. Small, nonpolar residues such as Thr in scyptolin or 2-amino-2-butenoic acid (Abu) in lyngbyastatin 7 are critical for inhibition of elastase and chymotrypsin, although more potent inhibition is observed for the former (Fig. 8).[152]

The marine cyanobacteria-derived members of this compound class bear the modified Thr residue, Abu moiety, at this position and are among the most potent elastase inhibitors. The structure-activity relationship studies on the compounds symplostatins 5–10 together with the X-ray cocrystal complex of lyngbyastatin 7-porcine pancreatic elastase provided key insights on other structural features that are critical for potent elastase inhibition (Figs. 8 and 9).[150] Having a polar functional group on residues that modify the N-terminus of the cyclodepsipeptide scaffold together with an N-Me-Tyr moiety on the macrocycle provides significant improvements to biological activity.[150]

Comprehensive protease screening using a panel of 68 proteases and 26 serine proteases for lyngbyastatin 7 and symplostatin 5, respectively, revealed that these compounds are not promiscuous inhibitors and inhibit only a subset of serine proteases with elastase being most potently inhibited, followed by bovine chymotrypsin.[150] With the information that members of the Abu-containing cyclic depsipeptides indeed are selective and potent elastase inhibitors, these compounds were utilized to modulate the cellular effects of elastase on bronchial epithelial cells. Elastase is a key player involved in the progression of chronic obstructive pulmonary disease (COPD), which is a major health concern due to the lack of effective therapeutics and surging patient populations.[153]

Fig. 9

Bronchial epithelial cells were stimulated with elastase together with either solvent control or the model compound symplostatin 5 (Fig. 8). Elastase treated cells showed changes in morphology, adhesion and growth, due in part to global transcript changes, upregulation of caspase activity, NF-κB nuclear translocation and cleavage of intercellular adhesion molecule-1 (ICAM-1).[150] Elastase caused significant upregulation of the transcript levels of pro-inflammatory cytokines *IL1A*, *IL1B* and *IL8*, together with transcription factors and components of the spliceosome and cell cycle (Fig. 9).[150] Symplostatin 5 was able to attenuate the cellular effects of elastase providing cytoprotection to bronchial epithelial cells and alleviating several of the hallmarks of COPD such as inflammation, detachment and cell death (Fig. 9).[150] Symplostatin 5 promises to possess a wide therapeutic window since it did not cause any cytotoxic effects to bronchial epithelial cells and had almost no transcriptional effects on cells that have not been stimulated with elastase. Aside from demonstrating the pharmacological utility of symplostatin 5 and related compounds as small molecule therapeutics, monitoring of the effects of elastase with an elastase-selective inhibitor provided insights into the cellular consequences of the proteolytic activity of elastase on bronchial epithelial cells. The comprehensive and global assessment of the effects of elastase on transcript levels indicates that elastase modulates the expression of a plethora of genes, with several of these having a yet-to-be determined relationship.

3.3.2 ASPARTIC PROTEASES

Three modified linear peptides, grassystatins A–C (Fig. 10A), were purified from a *Lyngbya* cf. *confervoides* collection.[154] These compounds bear a Leu-derived γ-amino-β-hydroxy acid, previously described in the broad-spectrum aspartic protease inhibitor pepstatin A (Fig. 10A).[154] The structural similarity between grassystatins and pepstatin A provided insights into the possible molecular target of the former as aspartic proteases.[154] Grassystatins A–C potently inhibited the aspartic proteases cathepsin D and E, but did not affect other members of this protease family such as renin and BACE1 (Fig. 10B).[154] Validation of the protease screening results indeed showed that grassystatins are potent cathepsins D and E inhibitors with pico- to nanomolar IC$_{50}$s, with preferential targeting of cathepsin E (Fig. 10B). Molecular docking studies of grassystatins A and C with cathepsins D and E were performed in order to visualize the molecular interactions of these inhibitors and, in addition, compare the interactions with that of pepstatin A to explain the differences in potency and selectivity (Fig. 10C).[154] Grassystatins A and B both bear L-Asn, while grassystatin C has N-Me-L-Gln that occupies the P2 site, in contrast, to L-Val of pepstatin A.[154] Molecular docking studies indicated that a basic residue at P2 confers selectivity for cathepsin E. The potent inhibitory activity of grassystatin A

was demonstrated to be due to the optimum length and complementarity of the functional groups of grassystatin A with the amino acid residues of cathepsin E in the binding pocket, based on the molecular docking studies (Fig. 10C). The *N*-Me-L-Asn unit of grassystatin A also contributes hydrogen bonding interactions with Gln303, while the *O*-Me-Pro residue forms extensive hydrogen bonding interactions with Gln85.[154]

Fig. 10

Although structurally related, cathepsins D and E have distinct cellular functions and, as such, it is important to have selective inhibitors that can distinguish between these two proteases. Among other things, cathepsin D is involved in programmed cell death, while cathepsin E has been implicated in the breakdown of antigenic peptides that leads to T cell proliferation and consequent increase in pro-inflammatory cytokines, indicating involvement in autoimmune diseases.[155] Grassystatin A showed potent and selective inhibition of cathepsin E; thus its effects on antigen presentation were evaluated by monitoring antigen presenting cells in human peripheral blood mononuclear cells stimulated with tetanus toxin C-fragment and in a mixed lymphocyte reaction of dendritic cells propagated in the CD4+ T cells, TT_c and phorbol myristate acetate.[154] Grassystatin A significantly lowered the proliferation of T cells in response to the exogenous antigen tetanus toxin C-fragment in human peripheral blood mononuclear cells. Furthermore, grassystatin A also decreased the proliferation of T cells in the autologous mixed lymphocyte reaction and significantly reduced the levels of the pro-inflammatory mediators IL-17 and IFN-γ.[154] The potent and selective cathepsin E-inhibitory activity of grassystatin A, combined with cell permeability and cellular activity, is key to its use as a molecular probe to characterize the functions of cathepsin E in pathways of autoimmune disease. In this light, the synthesis of grassystatin A was reported as well as its utility as a probe for the role of cathepsin E in MHC Class II-dependent antigen processing.[156] Inhibition of cathepsin E, via grassystatin A treatment, did not show any relevant role in ovalbumin antigen processing and peptide presentation, which was distinct from studies with other aspartic protease inhibitors.[156] Similarly, the related statine-bearing compound, symplocin A (Fig. 10A), from a *Symploca* sp. collection also demonstrated selective and potent inhibitory activity against cathepsin E.[157]

Fig. 11

Like the grassystatins, the phenylstatine-bearing peptide tasiamide B[158,159] (Fig. 11) also exhibited aspartic protease inhibitory activity but with a different selectivity profile.[160] Tasiamide B inhibited β-secretase 1 (BACE1) and cathepsins D and E with nanomolar IC_{50}s.[160] The selectivity of these compounds was probed using X-ray cocrystallization of tasiamide B and BACE1.[160] Tasiamide B occupies the binding groove between the C-terminal and N-terminal lobes of BACE1, and creates hydrogen bonding interactions with the residues of BACE1 including Gly34, Pro70, Thr72, Gln73, Tyr178, Gly230 and Thr232, in addition to 30 hydrophobic interactions with the enzyme.[160] Based on the SAR results for the proteolytic activity of tasiamide B and its analogs against cathepsins D and E, the selectivity can be fine-tuned by modifying the residues on both the C- and N-termini of the molecule.[160]

BACE1 is the key β-secretase involved in the proteolytic processing of the amyloid precursor protein to generate Aβ peptides linked to the formation of plaques in the brain, one of the important factors implicated in the pathogenesis of Alzheimer's disease. To probe the cellular consequences of tasiamide B and analogs on BACE1 inhibition, the levels of Aβ, Aβ40 and Aβ42 peptides *in vitro* and *in vivo* were monitored.[160] Tasiamide B reduced sAPPβ secretion in stably transfected H4 cells by approximately 50% at 10 µM concentration and also caused a significant reduction in the levels of total Aβ, Aβ40 and Aβ42 in CHO 2B7 cells, with an approximate IC_{50} of 10 µM.[160] With tasiamide B showing significant cellular effects relating to β-amyloid production as a consequence of BACE1 inhibition, this compound then served as an important prototype in designing more potent inhibitors of BACE1 with improved cellular activity. Since the P2 site has been demonstrated to be important for inhibition of aspartic proteases, synthetic analogs of tasiamide B were designed to incorporate modifications to the moiety occupying this site, while maintaining the central phenylstatine moiety and the C-terminus portion of tasiamide B.[160] The most potent analogs with cellular activity that were designed bear an isophthalic acid moiety which contributes to increased hydrogen bonding and hydrophobic interactions with BACE1 to achieve higher potency (Fig. 11).[160] Compared with tasiamide B, these hybrid compounds more potently reduced secreted sAPPβ, total Aβ, Aβ40 and Aβ42 levels.[160] The increased cellular activity for the tertiary (N-methyl) sulfonamide (Fig. 11) translated into *in vivo* activity. This compound demonstrated sufficient pharmacokinetic stability and blood-brain barrier penetration and together with the potent inhibitory activity against BACE1, resulted in significant reduction by 23% of Aβ40 levels in CF-1 mice treated with a 30 mg/kg dose (Fig. 11).[160]

3.4 Voltage-gated Ion Channel Modulation

Modulation of the activity of ion channels is also a prominent theme in the MOA of small molecules from marine cyanobacteria (Fig. 12).[19] The MOA of these compounds was probed using small molecule agonists and antagonists of ion channels and downstream effector proteins. Among the most widely studied ion channel modulators from cyanobacteria is antillatoxin A (Fig. 12), an ichthyotoxic compound, discovered by screening a library of cyanobacterial extracts for sodium channel modulators using mouse neuroblastoma cells.[161–163] Antillatoxin A showed a 10-fold higher potency compared to its analog antillatoxin B in activating voltage gated sodium channels (VGSCs).[163] Further neurochemical and pharmacological approaches were utilized to elucidate the MOA of antillatoxin A. Antillatoxin A caused neuronal loss in cerebellar granule cells, which was prevented by either tetrodotoxin or the NMDA receptor antagonists MK-801 and dextrorphan, reminiscent of the effects of brevetoxin and domoic acid, and suggested that the neurotoxic effects of antillatoxin A are mediated by VGSCs.[164] The effects of antillatoxin A on the influx of Ca^{2+} were also examined by monitoring fluo-3, a fluorescence indicator of intracellular $[Ca^{2+}]$. Antillatoxin A increased Ca^{2+} levels and this was abrogated by pretreatment of cells with tetrodotoxin. In order to probe for the interaction of antillatoxin A on VGSCs, the binding of [^{3}H]batrachotoxin to VGSCs was monitored in the presence of antillatoxin A.[164] A concentration-dependent stimulation of [^{3}H]batrachotoxin binding was observed with antillatoxin A. A synergistic effect was found with a combination of antillatoxin A and brevetoxin, but not with the

sea anemone toxin or deltamethrin. The increase in binding of [^{3}H]batrachotoxin was due to the allosteric modulation mediated by antillatoxin A. These data indicated that antillatoxin A is unlikely to bind to the neurotoxin sites 1, 2, 3, 5 and 7 on sodium channels and may either bind on a distinct site or at the neurotoxin site 4.[164] The pharmacological properties and selectivity of antillatoxin A was further evaluated using cells that heterologously express rNa$_v$1.2, rNa$_v$1.4 or rNa$_v$1.5 α-subunits. [Na$^+$] influx was monitored using the Na$^+$ binding dye benzofuran isophthalate.[165] Antillatoxin A induced Na$^+$ influx in all three cell types, and there were no significant differences in the efficacy of Na$^+$ influx in the three cell types. The pharmacological profile of antillatoxin A-induced Na$^+$ influx was distinct from that of other neurotoxins that bind to sites 2 and 5 of VGSCs. The cellular consequences of antillatoxin A-mediated Na$^+$ influx included neurite outgrowth in immature cerebrocortical neurons.[166] The signaling pathway modulated by antillatoxin A leading to neuritogenesis was probed using chemical inhibitors and by monitoring changes in neurite outgrowth and Na$^+$ and Ca^{2+} levels. Antillatoxin A activated VGSCs, leading to an increase in Na$^+$ levels. This was accompanied by an activation of the Src kinase family, leading to potentiation of NMDAR function, which culminated in Ca^{2+} influx, engagement of Ca^{2+}/calmodulin-dependent protein kinase and eventually neurite outgrowth.[166]

Fig. 12

Another class of neurotoxins from marine cyanobacteria is the hoiamide family, unique lipopeptides distinguished by contiguous heterocyclic ring systems consisting of two methylated thiazolines and one thiazole ring.[167–169] Using a bioactivity-directed approach, hoiamide A (Fig. 12) was purified as the active principle, causing a dose-dependent and rapid influx of [Na$^+$] in neocortical neurons.[167] Hoiamide A, however, produced a maximum Na$^+$ influx less than the full VGSC agonist batrachotoxin, suggesting that hoiamide A is a partial agonist.[167] The MOA of hoiamide A was interrogated using the VGSC inhibitor tetrodotoxin, NMDA receptor antagonist MK-801 and AMPA receptor antagonist NBQX, monitoring for hoiamide A-induced elevation in [Na$^+$] in neocortical neurons.[167] Tetrodotoxin A and MK-801, but not NBQX, caused a significant decrease in hoiamide A-induced Na$^+$ influx and an increase in maximum response of Na$^+$ influx with pyrethroid and brevetoxin 3 cotreatment.[167] This indicated a positive allosteric interaction between the hoiamide A binding site and neurotoxin sites 5 and 7, and suggested that hoiamide A occupies neurotoxin site 2.[167] Hoiamide A inhibited the specific binding of [^{3}H]batrachotoxin on neurotoxin site 2, which provided direct evidence for the interaction of hoiamide A with VGSC, and also reduced the maximum Na$^+$ influx in response to batrachotoxin, which is consistent with the reported interaction between a full and partial agonist. These results suggested that hoiamide A and batrachotoxin interact in a mutually exclusive manner with a common recognition site on VGSC.[167] The structural similarity between hoiamides A and B suggested that the latter also exhibited similar pharmacological effects. Further assays with hoiamide B indeed showed increased [Na$^+$] and suppression in Ca^{2+} oscillations.[168] The effects of both hoiamides A and B on Ca^{2+} oscillations were of higher potency compared to the effects on Na$^+$ influx, and were not related to the effects on VGSCs, suggesting that hoiamides A and B may have additional molecular target leading to the

observed pharmacological effects in Na$^+$ influx and Ca^{2+} oscillations.[168]

The neurotoxin kalkitoxin (Fig. 12), an unusual thiazoline-bearing lipid, was originally purified as the cytotoxic component using brine shrimp and fish toxicity.[170] The neurotoxic effect of kalkitoxin was demonstrated in primary cultures of rat neurons; this cellular effect of kalkitoxin was alleviated by cotreatment with an NMDA receptor antagonist.[162] Initial assessment indicated that kalkitoxin is a potent VGSC inhibitor, with comparable potency as saxitoxin in neuro-2a cells. Kalkitoxin inhibited veratridine-induced neurotoxicity and [Ca^{2+}] release and decreased [^{3}H]batrachotoxin incorporation in cells cotreated with deltamethrin, which suggested that kalkitoxin and pyrethroid binding sites may be allosterically coupled.[171] Additional studies on kalkitoxin, as well as other neuroactive compounds purified from marine cyanobacteria (Fig. 12) including the macrolide palmyrolide,[172] modified peptide alotamide[173] and the lipopeptide jamaicamides A–C,[174] are needed to establish the detailed MOA.

4 Mechanisms of Action and Direct Targets of Biologically Active Cyanobacteria Metabolites in Microbial and Protozoal Pathogens

The discovery of novel drug targets for antiprotozoal agents and antibiotics is of great interest particularly in tackling drug resistance. Small molecules that have unique molecular targets and mechanisms of action compared with currently available drugs can provide insight into alternative pathways that may be exploited to combat drug resistant strains of bacterial pathogens and protozoa.[175–177] Equally important is finding new molecular targets in bacteria and protozoa that are not utilized by their mammalian host, thereby giving the possibility of an improved selectivity window and minimizing undesirable side effects.

Fig. 13

4.1 Falcipains

The modified linear peptide symplostatin 4 (Fig. 13), also referred to as gallinamide A, was independently purified from *Symploca* and *Schizothrix* by the Luesch and Linington groups, respectively.[48,178] Synthesis of symplostatin 4/gallinamide A and isomers indicated that these two compounds are indeed identical.[179] Symplostatin 4 was demonstrated to induce G2 cell cycle arrest at high-micromolar concentration, which is related to the microtubule disrupting effects as evidenced by immunofluorescence staining of tubulin in HeLa cells.[48] In addition, symplostatin 4 was purified as the antimalarial constituent using a bioactivity-directed fractionation of a *Schizothrix* collection.[178] Symplostatin 4 and synthetic analogs showed potent activity against drug resistant and wild-type strains of *Plasmodium falciparum*.[179,180] Interestingly, symplostatin 4 did not cause lysis of red blood cells, even at high-micromolar concentration.[181] Clues to the mechanism of antiplasmodial activity of symplostatin 4 were obtained from the distinct food vacuole phenotype of *P. falciparum* observed following symplostatin 4 treatment.[181] Giemsa stained ring stage parasites treated with symplostatin 4 showed a red

swollen food vacuole phenotype.[181] This phenotype is characteristic, arising from accumulation of nondigested hemoglobin or oligopeptides in the food vacuole due to inhibition of proteases involved in this pathway, and thus delineated the possible cellular targets of symplostatin 4 in *P. falciparum*.[181] A rhodamine (Rh) labeled molecule was prepared to visualize target proteins in the intact schizont.[181] Following protein isolation, SDS-PAGE analysis showed two bands in the 28 kDa molecular weight range to be strongly labeled by symplostatin 4.[181] The formation of the food vacuole phenotype, together with the bands observed with treatment of Rh-labeled symplostatin 4 and the importance of the methylmethoxypyrrolinone moiety in symplostatin 4 suggested its possible role in the inhibition of one or more types of falcipains, which are plasmodial papain-like Cys proteases.[181] Symplostatin 4 was shown to target falcipains 2/2' and 3 using a competitive activity-based protein profiling (ABPP) experiment employing Cy5-DCG-04 as the activity based probe for papain-like Cys proteases.[181] Symplostatin 4 was further demonstrated to be an irreversible inhibitor of falcipains 2 and 3, through analysis of the substrate turnover using recombinant falcipains.[181] The effects of symplostatin 4 on other Cys proteases were also evaluated; cathepsin L was identified as the predominant mammalian cellular target.[181] A follow up study indicated that symplostatin 4 is a covalent inhibitor of cathepsin L, using the vinyl amino acid derived moiety as the warhead.[182] Symplostatin 4 has an IC_{50} of 5.0 nM against mammalian cathepsin L,[182] although the direct consequence of this activity in mammalian cells treated with symplostatin 4 is not evident at this point. Hence, determination of off-target cellular effects of cathepsin L inhibition is warranted. The selective inhibition of symplostatin 4 on falcipains established this compound as a useful pharmacological probe and also suggests an alternative therapeutic target in combating the *Plasmodium* spp. parasites.

4.2 Glycosomes

The linear lipopentapeptide almiramides A–C (Fig. 13) were isolated from a *Lyngbya majuscula* collection as the active principle against the parasite *Leishmania donovania*, the causative agent of leishmaniasis.[183] The close relation of this parasite to other kinetoplastid parasites such as *Trypanosoma brucei* prompted its evaluation for additional biological activity.[184] Almiramides A–C and related synthetic analogs showed low micromolar IC_{50}s against both *Leishmania* sp. and *T. b. brucei*, with the majority of the compounds having greater than 10-fold selectivity for the parasites than mammalian cells.[184] The MOA of almiramides against *T. brucei* was interrogated using an almiramide C-biotinylated probe, photoaffinity probe and affinity-resin conjugated probe. The use of complementary techniques to search for the direct target of almiramides addressed the limitations of each technique and thereby provided greater reliability of the protein hits from affinity purification.[184] The biotinylated probe was constructed using a commercially available biotin reporter tag with a primary amine terminus that was coupled to an almiramide C analog bearing a terminal carboxylic acid moiety.[184] Incubation

of the biotinylated probe with cell lysates of *T. brucei* yielded 38 possible protein targets.[184] The affinity resin on the other hand was prepared using a 15 Å PEG linker and a 6-aminohexanol-capped affi-gel resin and identified 12 proteins that directly bind to almiramide.[184] The photoaffinity probe was prepared like the biotinylated probe, except for the addition of a benzophenone moiety. It relied on the generation of short-lived carbene species following irradiation of the biotinylated probe and cell lysates with UV, and identified 73 possible protein targets.[184] Integration of the results of the three methods identified seven common candidate proteins, including β-tubulin, elongation factor 1-α, and five glycosomal proteins: glycosomal membrane protein, glycerol kinase, glyceraldehyde 3-phosphate dehydrogenase, Gim 5A protein and orotidine 5-phosphate decarboxylase.[184] β-Tubulin and elongation factor 1-α were suggested to be false-positive targets because of their cellular abundance, and almiramides are then likely to affect the glycosomes of *T. brucei*, which is the sole energy machinery of these parasites.[184] Almiramides exert a novel mechanism of inhibition of *T. brucei*, are the first small molecules shown to inhibit glycosomal function, and are an attractive chemotherapeutic target since glycosomes have no mammalian homologs.[184] Validation of the direct target of almiramides, however, proved to be difficult due to limitations in expressing glycosomal-encoding genes.[184]

4.3 Quorum Sensing

Small molecule inhibitors of bacterial quorum sensing were also isolated from marine cyanobacteria, with several of these compounds showing structural similarities to acylhomoserine lactones (AHLs) used by Gram-negative bacteria to regulate quorum sensing. AHLs can bind to intercellular receptor proteins which leads to activation of gene expression pathways relevant to biofilm formation, virulence, luminescence and other quorum sensing-dependent phenotypes.[185] The bioactivity of quorum sensing inhibitors was demonstrated through transcript and protein level monitoring of relevant quorum sensing genes such as *lasB* and *phzG1*, pyocyanin pigment production in *Pseudomonas aeruginosa*, and measurement of quorum sensing-dependent phenotype such as bioluminescence in *Vibrio harveyi*.[186] Quorum sensing may be regulated by small molecules through competition for the AHL binding site, downregulation of expression of quorum sensing genes or regulation of the quorum sensing repressor RsaL.[186]

Fig. 14

Using a bioactivity-directed isolation, malyngolide (Fig. 14) was purified as the anti-quorum sensing component.[187] Malyngolide, at a sublethal concentration, acts as an indirect quorum sensing inhibitor, preventing the response of lasR+lasI+luxCDABE reporter pSB1075 in the presence of *N*-oxo-dodecanoyl-L-homoserine lactone (C_6-HSL).[187] Malyngolide, however, did not affect the quorum sensing-dependent phenotype of *Agrobacterium tumanifaciens* reporter, in the presence or absence of C_6-HSL stimulation, suggesting

that malyngolide does not act as a direct agonist or antagonist of quorum sensing.[187] To further validate the effects of malyngolide in attenuating bacterial quorum sensing, the production of elastase, which is controlled by 3-oxo C_{12}-HSL and LasR, was monitored. Malyngolide inhibited elastase production, while the exact MOA of malyngolide is yet to be fully elucidated.[187] Accordingly, the structural relatedness of the tumonoic acids to AHLs prompted their evaluation for quorum sensing inhibition. Tumonoic acids E–H modulated the quorum sensing-dependent bioluminescence in *V. harveyi*, with tumonoic acid F being the most potent.[188]

The similarity of the cyclopropane "tagged" fatty acid lyngbyoic acid (Fig. 14) with structures of natural AHL disrupters prompted investigations of its effects on quorum sensing.[189] Lyngbyoic acid was evaluated in three *E. coli* reporter strains (pSB401, pSB536 and pSB1075), in the presence or absence of cognate AHLs. These reporters encode for different transcriptional activator proteins (R proteins) and, consequently, differ in their response to cognate AHLs. Lyngbyoic acid had the greatest inhibitory activity in the pSB1075 reporter system in the presence of 3-oxo-C_{12}-AHL, while decreasing the background luminescence for all three reporters in the absence of AHLs.[189] Using the pTIM5319 reporter which is similar to pSB1075 but lacked the AHL-binding site, lyngbyoic acid also reduced background luminescence, indicating that the effects of lyngbyoic acid on quorum sensing depend on neither the cognate AHL nor the AHL-binding domain of the receptor.[189] In the pTIM505pTIM5211 reporter, which lacks the transcriptional repressor *rsaL*, 3-oxo-C_{12}-HSL was able to compete with lyngbyoic acid, indicating that the effects of lyngbyoic acid are mediated by both AHL-binding domain-dependent and independent mechanisms. Unlike the related dodecanoic acid, lyngbyoic acid decreased pyocyanin and elastase production in wild-type *P. aeruginosa* cultures, due in part to downregulation of *lasB* and *phzG1* transcript levels but also directly inhibited elastase.[189]

Analysis of the global changes in the transcriptome of *P. aeruginosa* PAO1 treated with lyngbyoic acid using microarray analysis revealed 969 upregulated genes and 887 downregulated genes in response to treatment.[189] Relevant genes in pyocyanin production, secreted enzymes and rhamnolipid production were significantly downregulated, together with iron-regulated and biofilm-relevant genes being differentially expressed as well.[189] The results of the transcriptome analysis of lyngbyoic acid-treated PAO1 indicated that this compound may serve as a useful molecular tool to probe for process adaptation of *P. aeruginosa* in cystic fibrosis patients and to elucidate the role of fatty acids as pathway modulators.[189]

5 Multiple Modes of Inhibition Mediated by Biologically Active Cyanobacteria Metabolites

The modified fatty acid esters honaucins A–C and pitinoic acids A–C (Fig. 15) represent a class of cyanobacterial

compounds that consists of two structurally distinct simple carbon-chain components fused by an ester linkage. Presumably upon hydrolysis of the ester bond, these "modular" compounds deliver two different molecules that have distinct biological activities and, hence, display bifunctional activities. Honaucin A consists of a (S)-3-hydroxy-γ-butyrolactone and 4-chlorocrotonic acid, while honaucins B and C both bear a 3,4-di-*O*-substituted butanoic acid.[190] Pitinoic acid B, on the other hand, consists of pitinoic acid A (5-methylene decanoic acid) and pitinoic acid C (5-chloro-2-hydroxy-pent-4-enoic acid). Pitinoic acids A and C were also purified as individual components of the crude extract.[191]

Fig. 15

The structural similarities of honaucins A–C with microbial signaling small molecules prompted their evaluation as bacterial quorum sensing inhibitors, dose-dependently inhibiting bioluminescence, a quorum sensing-dependent phenotype in *V. harveyi* BB120.[190] Honaucins were further evaluated by monitoring GFP-fluorescence arising from the activation of the LuxR receptor via the exogenous autoinducer 3-oxo-hexanoyl homoserine lactone in *Escherichia coli* JB525.[190] Testing of synthetic analogs of honaucins confirmed the importance of the γ-butyrolactone ring, the position and configuration of the OH group on the γ-butyrolactone moiety, presence and position of the double bond, carbon chain length and nature of the halogen.[190] Further evaluation of the natural and synthetic honaucins indicated that these compounds can inhibit lipopolysaccharide (LPS) mediated nitric oxide production in RAW macrophage cells, and the same structural features for the quorum sensing modulation were deemed essential for this biological activity in mammalian cells.[190] Evaluation of the mechanism of inhibition of nitric oxide production indicated downregulation of the mRNA expression of several important inflammatory mediators such as TNF-α, IL-1β, IL-6 and iNOS by honaucin A.[190]

The structural similarity between honaucins and pitinoic acid B prompted the evaluation of the latter for anti-inflammatory effects using LPS-stimulated THP cells.[191] Ester pitinoic acid B and its alcohol component, pitinoic acid C, downregulated the expression of several pro-inflammatory interleukins (IL-1β, IL-6 and IL-8) as well as TNF-α.[191] Pitinoic acid A was also evaluated for its quorum sensing inhibitory activity due to the precedence of such effects of related fatty acids such as lyngbyoic acid.[191] Pitinoic acid A decreased the transcript level of *lasB* and pyocyanin biosynthetic member *phzG1* and, in accord, decreased elastase and pyocyanin levels in culture supernatants of *P. aeruginosa*.[191]

Symplostatin 4 is another example of a bifunctional molecule that has both mammalian and protozoal targets. Instead of delivering two different molecules upon metabolic activation, two distinct regions of the molecule bind to different targets. The N-terminus of dolastatin 10 related compounds has been shown to be critical to modulating tubulin polymerization based on SAR results, suggesting that the N-terminus of symplostatin

4 is key to the observed antiproliferative and tubulin disrupting activity.[48] In addition, the pentenoic acid-derived moiety in the C-terminus of symplostatin 4 is detrimental to the antiproliferative activity, as observed for analogs of dolastatin 10 bearing the same modification. Based on the SAR for symplostatin 4 against *P. falciparum*, it is clear that the unusual methyl-methoxypyrrolinone moiety in the C-terminus of the molecule is central to targeting the falcipains of this protozoal parasite by forming a covalent adduct.[181] The α,β-unsaturated system in the C-terminus of symplostatin 4 is determinant for the formation of a covalent bond with a Cys residue of cathepsin L.[182]

The presence of distinct moieties in cyanobacterial small molecules that can be liberated upon biotransformation gives rise to bifunctional biological activities and may represent a prodrug strategy employed by these primitive organisms. Prodrug strategies in general are quite commonly utilized by Nature.[192] Also, the presence of defined regions of the molecule that gives rise to biological activities toward mammalian cancer cells and bacterial or protozoan pathogens offers the opportunity for modulating potential off-target effects and improving the selectivity index.

6 Perspective

Marine cyanobacteria continue to be a rich source of structurally diverse and potent pharmacological agents. The potential utilities of these small molecules are now better realized with the establishment of the MOA and identification of molecular targets. Improvements in bioactivity screening technologies, chemical genomics and chemical proteomics techniques have further strengthened the value of cyanobacteria as source organisms for drug discovery and chemical biology. The elucidation of the mechanisms of action and targets of cyanobacterial small molecule has allowed for the discovery of novel molecular targets that offers a novel way for disease intervention. The targets of cyanobacterial small molecules extend well beyond commonly reported drug targets for mammalian, protozoal and bacterial systems, which may be exploited for tackling drug resistance and minimizing side effects. For example, aurilides represent the first small molecule modulators of prohibitin and, as such, aurilides will become a valuable chemical tool to elucidate the role of this protein in signaling networks related to cancer, and may potentially represent a novel approach in combating malignancies. Largazole, among the most potent and selective HDAC inhibitors to date, has also emerged as a tool to visualize the molecular interactions of depsipeptides with HDACs. This discovery will aid in the development of the next generation of cyclodepsipeptide-based inhibitors. The discovery of the molecular target of largazole has also widened the prospect for this cyanobacterial molecule. Aside from cancer-related applications, largazole is now also being pursued for other diseases where gene expression changes may be beneficial. The elucidation of the MOA has also benefited the design of new analogs of cyanobacterial compounds that possess improved potency and selectivity. Tasiamide B, which targets the important BACE1 enzyme, has yielded new analogs with potent *in vitro* and *in vivo* activity and pharmacokinetic stability. The antiprotozoal compounds symplostatin 4 and almiramides have given insights into new molecular targets for malaria and trypanosomiasis, respectively. The mechanisms of action of these antiprotozoal compounds provide a possible new route in tackling protozoal parasites with potentially fewer side effects to the human host. More importantly, deciphering the MOA also allowed for weeding out potential off-target effects of cyanobacterial small molecules. This has been beneficial for the potent antiproliferative agent apratoxin A and has enabled the design of new analogs without the irreversible toxicity that has limited the development of this small molecule. The elucidation of the bioactivity, SAR and mechanisms of action of the dolastatin 10 family of compounds highlights the privileged scaffold of these cyanobacterial metabolites. The primitive source organism of these compounds utilizes the same basic skeleton to target multiple diseases and cellular targets in cancer and malaria, with minimal overlap presumably through a switching mechanism. The tubulin disrupting and anticancer activity of the dolastatin 10 family of compounds relies on the N-terminal moieties for potent bioactivity and abrogated by the introduction of a double bond on the C-terminus. In contrast, the antiplasmodial properties of the dolastatin 10 family rely on the modified amino acid residues on the C-terminus.

The relevance of the MOA and direct targets of antiproliferative natural products to cancer is also related to a better understanding of the molecular basis of the disease. The molecular mechanisms of the unintended side effects of several promising cyanobacterial small molecules are poorly defined and would be of interest to trigger the development of these compounds as effective therapeutics in the future. In all, natural products discoveries offer a wider research prospective with the elucidation of the MOA and target. In the coming years, the development of new platforms in screening technologies, next-generation sequencing and use of model organisms such as *S. cerevisiae*, *C. elegans* and *D. rerio* will pave the way for the discovery of new small molecules from marine cyanobacteria and their pharmacological effects. As cyanobacterial natural products have shown exemplary activities towards their protein targets, it is warranted to explore cyanobacteria to discover small molecules against poorly understood diseases to find molecular probes and effective therapeutics as well.

Notes and references

[a] Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, USA. Email: luesch@cop.ufl.edu. Tel: 352-273-7738. Fax: 352-273-7741.
[b] Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida 32610, USA
[c] Marine Science Institute, College of Science, University of the Philippines, Diliman, Quezon City 1101, Philippines
Conflict of Interest

1 D. J. Newman and G. M. Cragg, *J. Nat. Prod.,* 2012, **75**, 311-335.

2 F. Cong, A. K. Cheung and S. A. Huang, *Annu. Rev. Pharmacol. Toxicol.,* 2012, **52**, 57-78.

3 O. Hurco, *Neurochem. Int.,* 2012, **61**, 892-898.

4 S. Ziegler, V. Pries, C. Hedberg and H. Waldmann, *Angew. Chem. Int. Ed.,* 2013, **52**, 2744-2794.

5 R. Breinbauer, I. R. Vetter and H. Waldmann, *Angew. Chem. Int. Ed.,* 2002, **41**, 2878-2890.

6 E. E. Carlson, *ACS Chem. Biol.,* 2010, **5**, 639-653.

7 J. Taunton, J. L. Collins and S. L. Schreiber, *J. Am. Chem. Soc.,* 1996, **118**, 10412-10422.

8 A. Vannini, C. Volpari, G. Filocamo, E. C. Casavola, M. Brunetti, D. Renzoni, P. Chakravarty, C. Paolini, R. De Francesco, P. Gallinari, C. Steinkuhler and S. Di Marco, *Proc. Natl. Acad. Sci. USA,* 2004, **101**, 15064-15069.

9 J. R. Somoza, R. J. Skene, B. A. Katz, C. Mol, J. D. Ho, A. J. Jennings, C. Luong, A. Arvai, J. J. Buggy, E. Chi, J. Tang, B. Sang, E. Verner, R. Wynands, E. M. Leahy, D. R. Dougan, G. Snell, M. Navre, M. W. Knuth, R. V. Swanson, D. E. McRee and L. W. Tari, *Structure,* 2004, **12**, 1325-1334.

10 J. Bolden, M. J. Peart and R. W. Johnstone, *Nat. Rev. Drug Discov.,* 2006, **5**, 769-784.

11 A. L. Hopkins and C. R. Groom, *Nat. Rev. Drug Discov.,* 2002, **1**, 727-730.

12 M. Muda and S. McKenna, *Drug Discov. Today,* 2004, **1**, 55-59.

13 C. P. Ridley, P. R. Bergquist, M. K. Harper, D. J. Faulkner, J. N. Hooper and M. G. Haygood, *Chem. Biol.,* 2005, **12**, 397-406.

14 M. S. Donia, B. J. Hathaway, S. Sudek, M. G. Haygood, M. J. Rosovitz, J. Ravel and E. W. Schmidt, *Nat. Chem. Biol.,* 2006, **2**, 729-735.

15 H. Luesch, G. G. Harrigan, G. Goetz and F. D. Horgen, *Curr. Med. Chem.,* 2002, **9**, 1791-1806.

16 W. H. Gerwick and B. S. Moore, *Chem. Biol.,* 2012, **19**, 85-98.

17 P. D. Senter and E. L. Sievers, *Nat. Biotechnol.,* 2012, **30**, 631-637.

18 L. T. Tan, *Drug Discov. Today,* 2013, **18**, 863-871.

19 L. T. Tan, *J. Appl. Phycol.,* 2010, **22**, 659-676.

20 L. T. Tan, *Phytochemistry (Elsevier),* 2007, **68**, 954-979.

21 R. H. Shoemaker, *Nat. Rev. Cancer,* 2006, **6**, 813-823.

22 R. L. Bai, K. D. Paull, C. L. Herald, L. Malspeis, G. R. Pettit and E. Hamel, *J. Biol. Chem.,* 1991, **25**, 15882-15889.

23 J. E. Staunton, D. K. Slonim, H. A. Coller, P. Tamayo, M. J. Angelo, J. Park, U. Scherf, J. K. Lee, W. O. Reinhold, J. N. Weinstein, J. P. Mesirov, E. S. Lander, P. O. Brown and T. R. Golub, *Proc. Natl. Acad. Sci. USA,* 2001, **98**, 10787-10792.

24 D. T. Ross, U. Scherf, M. B. Eisen, C. M. Perou, C. Rees, P. Spellman, V. Iyer, S. S. Jeffrey, M. Van de Rijn, M. Waltham, A. Pergamenschikov, J. C. Lee, D. Lashkari, D. Shalon, T. G. Myers, J. N. Weinstein, D. Botstein and P. O. Brown, *Nat. Genet.,* 2000, **24**, 227-235.

25 U. Scherf, D. T. Ross, M. Waltham, L. H. Smith, J. K. Lee, L. Tanabe, K. W. Kohn, W. C. Reinhold, T. G. Myers, D. T. Andrews, D. A. Scudiero, M. B. Eisen, E. A. Sausville, Y. Pommier, D. Botstein, P. O. Brown and J. N. Weinstein, *Nat. Genet.,* 2000, **24**, 236-244.

26 Y. Futamura, M. Kawatani, S. Kazami, K. Tanaka, M. Muroi, T. Shimizu, T. Tomita, N. Watanabe and H. Osada, *Chem. Biol.,* 2012, **19**, 1620-1630.

27 J. Lamb, *Nat. Rev. Cancer,* 2007, **7**, 54-60.

28 S. Wacker, B. Houghtaling, O. Elemento and T. Kapoor, *Nat. Chem. Biol.,* 2012, **8**, 235-237.

29 H. Luesch, *Mol. Biosyst.,* 2006, **2**, 609-620.

30 S. Sato, A. Murata, T. Shirakawa and M. Uesugi, *Chem. Biol.,* 2010, **17**, 616-623.

31 U. Rix and G. Superti-Furga, *Nat. Chem. Biol.,* 2009, **5**, 616-624.

32 Y. Futamura, M. Muroi and H. Osada, *Mol. Biosyst.,* 2013, **9**, 897-914.

33 M. Schenone, V. Dančík, B. K. Wagner and P. A. Clemons, *Nat. Chem. Biol.,* 2013, **9**, 232-240.

34 B. Lomenick, R. Hao, N. Jonai, R. M. Chin, M. Aghajan, S. Warburton, J. Wang, R. P. Wu, F. Gomez and F. Loo, *Proc. Natl. Acad. Sci. USA,* 2009, **106**, 21984-21989.

35 S. Y. Saito, *Prog. Mol. Subcell. Biol.,* 2009, **46**, 187-219.

36 C. Dumontet and M. A. Jordan, *Nat. Rev. Drug Discov.,* 2010, **9**, 790-803.

37 M. A. Jordan and L. Wilson, *Nat. Rev. Cancer,* 2004, **4**, 253-265.

38 M. A. Jordan and L. Wilson, *Curr. Opin. Cell Biol.,* 1998, **10**, 123-130.

39 R. Bai, G. Pettit and E. Hamel, *Biochem. Pharmacol.,* 1990, **39**, 1941-1949.

40 G. R. Pettit, Y. Kamano, C. L. Herald, C. Dufresne, R. L. Cerny, D. L. Herald, J. M. Schmidt and H. Kizu, *J. Am. Chem. Soc.,* 1989, **111**, 5015-5017.

41 G. G. Harrigan, H. Luesch, W. Y. Yoshida, R. E. Moore, D. G. Nagle, V. J. Paul, S. L. Mooberry, T. H. Corbett and F. A. Valeriote, *J. Nat. Prod.,* 1998, **61**, 1075-1077.

42 H. Luesch, R. E. Moore, V. J. Paul, S. L. Mooberry and T. H. Corbett, *J. Nat. Prod.,* 2001, **64**, 907-910.

43 S. L. Mooberry, R. M. Leal, T. L. Tinley, H. Luesch, R. E. Moore and T. H. Corbett, *Int. J. Cancer,* 2003, **104**, 512-521.

44 A. Mitra and D. Sept, *Biochemistry,* 2004, **43**, 13955-13962.

45 U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright and M. Hussain, *Clin. Cancer Res.,* 2000, **6**, 4205-4208.

46 C. Deng, B. Pan and O. A. O'Connor, *Nat. Rev. Drug Discov.,* 2011, **11**, 19-20.

47 H. Luesch, W. Y. Yoshida, R. E. Moore, V. J. Paul, S. L. Mooberry and T. H. Corbett, *J. Nat. Prod.,* 2002, **65**, 16-20.

48 K. Taori, Y. Liu, V. J. Paul and H. Luesch, *ChemBioChem,* 2009, **10**, 1634-1639.

49 F. D. Horgen, E. B. Kazmierski, H. E. Westenburg, W. Y. Yoshida and P. J. Scheuer, *J. Nat. Prod.,* 2002, **65**, 487-491.

50 T. L. Simmons, K. L. McPhail, E. Ortega-Barria, S. L. Mooberry and W. H. Gerwick, *Tetrahedron Lett.,* 2006, **47**, 3387-3390.

51 T. Golakoti, J. Ogino, C. E. Heltzel, T. L. Husebo, C. M. Jensen, L. K. Larsen, G. M. L. Patterson, R. E. Moore, S. L. Mooberry, T. H. Corbett and F. A. Valeriote, *J. Am. Chem. Soc.,* 1995, **117**, 12030-12049.

52 G. E. Chlipala, S. Mo and J. Orjala, *Curr. Drug Targets,* 2011, **12**, 1654-1673.

53 G. Trimurtulu, I. Ohtani, G. M. L. Patterson, R. E. Moore, T. H. Corbett, F. A. Valeriote and L. Demchiko, *J. Am. Chem. Soc.,* 1994, **116**, 4729-4737.

54 M. Kobayashi, S. Aoki, N. Ohyabu, M. Kurosu, W. Wang and I. Kitagawa, *Tetrahedron Lett.,* 1994, **35**, 7969-7972.

55 C. D. Smith, X. Zhang, S. L. Mooberry, G. M. Patterson and R. E. Moore, *Cancer Res.,* 1994, **54**, 3779-3784.

56 K. Morita, Y. Koiso, Y. Hashimoto, M. Kobayashi, W. Wang, N. Ohyabu and S. Iwasaki, *Biol. Pharm. Bull.,* 1997, **20**, 171-174.

57 D. Panda, V. Ananthnarayan, G. Larson, C. Shih, M. A. Jordan and L. Wilson, *Biochemistry,* 2000, **39**, 14121-14127.

58 M. J. Edelman, D. R. Gandara, P. Hausner, V. Israel, D. Thornton, J. DeSanto and L. A. Doyle, *Lung Cancer,* 2003, **39**, 197-199.

59 G. D'Agostino, J. del Campo, B. Mellado, M. A. Izquierdo, T. Minarik, L. Cirri, L. Marini, J. L. Perez-Gracia and G. Scambia, *Int. J. Gynecol. Cancer,* 2006, **16**, 71-76.

60 W. H. Gerwick, P. J. Proteau, D. G. Nagle, E. Hamel, A. Blokhin and D. L. Slate, *J. Org. Chem.,* 1994, **59**, 1243-1245.

61 P. Verdier-Pinard, N. Sitachitta, J. V. Rossi, D. L. Sackett, W. H. Gerwick and E. Hamel, *Arch. Biochem. Biophys.,* 1999, **370**, 51-58.

62 R. Dominguez and K. C. Holmes, *Annu. Rev. Biophys.,* 2011, **40**, 169-186.

63 J. A. Cooper, *J. Cell Biol.,* 1987, **105**, 1473-1478.

64 G. R. Pettit, Y. Kamano, C. L. Herald, Y. Fujii, H. Kizu, R. R. Boyd, F. E. Boettner, D. L. Doubek, J. M. Schmidt, J. Chapuis and C. Michel, *Tetrahedron,* 1993, **49**, 9151-9170.

65 R. Bai, P. Verdier-Pinard, S. Gangwar, C. C. Stessman, K. J. McClure, E. A. Sausville, G. R. Pettit, R. B. Bates and E. Hamel, *Mol. Pharmacol.,* 2001, **59**, 462-469.

66 T. Oda, Z. D. Crane, C. W. Dicus, B. A. Sufi and R. B. Bates, *J. Mol. Biol.,* 2003, **328**, 319-324.

67 D. E. Williams, D. L. Burgoyne, S. J. Rettig, R. J. Andersen, Z. R. Fathi-Afshar and T. M. Allen, *J. Nat. Prod.,* 1993, **56**, 545-551.

68 P. G. Williams, R. E. Moore and V. J. Paul, *J. Nat. Prod.,* 2003, **66**, 1356-1363.

69 G. G. Harrigan, W. Y. Yoshida, R. E. Moore, D. G. Nagle, P. U. Park, J. Biggs, V. J. Paul, S. L. Mooberry, T. H. Corbett and F. A. Valeriote, *J. Nat. Prod.,* 1998, **61**, 1221-1225.

70 H. Luesch, W. Y. Yoshida, R. E. Moore, V. J. Paul and S. L. Mooberry, *J. Nat. Prod.,* 2000, **63**, 611-615.

71 H. Luesch, W. Y. Yoshida, R. E. Moore and V. J. Paul, *J. Nat. Prod.,* 2000, **63**, 1437-1439.

72 B. Han, K. L. McPhail, H. Gross, D. E. Goeger, S. L. Mooberry and W. H. Gerwick, *Tetrahedron,* 2005, **61**, 11723-11729.

73 S. Matthew, L. A. Salvador, P. J. Schupp, V. J. Paul and H. Luesch, *J. Nat. Prod.,* 2010, **73**, 1544-1552.

74 B. L. Marquez, K. S. Watts, A. Yokochi, M. A. Roberts, P. Verdier-Pinard, J. I. Jimenez, E. Hamel, P. J. Scheuer and W. H. Gerwick, *J. Nat. Prod.,* 2002, **65**, 866-871.

75 E. Sumiya, H. Shimogawa, H. Sasaki, M. Tsutsumi, K. Yoshita, M. Ojika, K. Suenaga and M. Uesugi, *ACS Chem. Biol.,* 2011, **6**, 425-431.

76 G. M. Patterson, C. D. Smith, L. H. Kimura, B. A. Britton and S. Carmeli, *Cell Motil. Cytoskeleton,* 1993, **24**, 39-48.

77 D. Hanahan and R. A. Weinberg, *Cell,* 2000, **100**, 57-70.

78 D. Hanahan and R. A. Weinberg, *Cell,* 2011, **144**, 646-674.

79 H. Luesch, W. Y. Yoshida, R. E. Moore, V. J. Paul and T. H. Corbett, *J. Am. Chem. Soc.,* 2001, **123**, 5418-5423.

80 H. Luesch, W. Y. Yoshida, R. E. Moore and V. J. Paul, *Tetrahedron,* 2002, **58**, 7959-7966.

81 H. Luesch, W. Y. Yoshida, R. E. Moore and V. J. Paul, *Bioorg. Med. Chem.,* 2002, **10**, 1973-1978.

82 S. Matthew, P. J. Schupp and H. Luesch, *J. Nat. Prod.,* 2008, **71**, 1113-1116.

83 M. Gutierrez, T. L. Suyama, N. Engene, J. S. Wingerd, T. Matainaho and W. H. Gerwick, *J. Nat. Prod.,* 2008, **71**, 1099-1103.

84 K. Tidgewell, N. Engene, T. Byrum, J. Media, T. Doi, F. A. Valeriote and W. H. Gerwick, *ChemBioChem,* 2010, **11**, 1458-1466.

85 H. Luesch, S. K. Chanda, R. M. Raya, P. D. DeJesus, A. P. Orth, J. R. Walker, J. C. Izpisua Belmonte and P. G. Schultz, *Nat. Chem. Biol.,* 2006, **2**, 158-167.

86 Y. Liu, B. K. Law and H. Luesch, *Mol. Pharmacol.,* 2009, **76**, 91-104.

87 S. Shen, P. Zhang, M. A. Lovchik, Y. Li, L. Tang, Z. Chen, R. Zeng, D. Ma, J. Yuan and Q. Yu, *J. Cell Biol.,* 2009, **185**, 629-639.

88 Q. Y. Chen, Y. Liu and H. Luesch, *ACS Med. Chem. Lett.,* 2011, **2**, 861-865.

89 Q. Y. Chen, Y. Liu, W. Cai and H. Luesch, *J. Med. Chem.,* 2014, **57**, 3011-3029.

90 B. C. Smith and J. M. Denu, *Biochim. Biophys. Acta,* 2009, **1789**, 45-57.

91 B. C. Smith, W. C. Hallows and J. M. Denu, *Chem. Biol.,* 2008, **15**, 1002-1013.

92 T. Kouzarides, *Cell,* 2007, **128**, 693-705.

93 L. A. Salvador and H. Luesch, in *Natural Products and Cancer Drug Discovery, Cancer Drug Discovery and Development,* ed. F. E. Koehn, Springer, New York, 2013, pp. 59-94.

94 A. Ganesan, L. Nolan, S. J. Crabb and G. Packham, *Curr. Cancer Drug Targets,* 2009, **9**, 963-981.

95 R. Furumai, A. Matsuyama, N. Kobashi, K. Lee, M. Nishiyama, H. Nakajima, A. Tanaka, Y. Komatsu, N. Nishino, M. Yoshida and S. Horinouchi, *Cancer Res.,* 2002, **62**, 4916-4921.

96 E. Lech-Maranda, E. Robak, A. Korycka and T. Robak, *Mini-Rev. Med. Chem.,* 2007, **7**, 1062-1069.

97 P. A. Marks and R. Breslow, *Nat. Biotechnol.,* 2007, **25**, 84-90.

98 I. C. Pina, J. T. Gautschi, G. Wang, M. L. Sanders, F. J. Schmitz, D. France, S. Cornell-Kennon, L. C. Sambucetti, S. W. Remiszewski, L. B. Perez, K. W. Bair and P. Crews, *J. Org. Chem.,* 2003, **68**, 3866-3873.

99 W. Gu, M. Cueto, P. R. Jensen, W. Fenical and R. B. Silverman, *Tetrahedron,* 2007, **63**, 6535-6541.

100 J. Hong and H. Luesch, *Nat. Prod. Rep.,* 2012, **29**, 449-456.

101 K. Taori, V. J. Paul and H. Luesch, *J. Am. Chem. Soc.,* 2008, **130**, 1806-1807.

102 C. Pavlik, C. Wong, S. Ononye, D. D. Lopez, N. Engene, K. L. McPhail, W. H. Gerwick and M. J. Balunas, *J. Nat. Prod.,* 2013, **76**, 2026-2033.

103 Y. Ying, K. Taori, H. Kim, J. Hong and H. Luesch, *J. Am. Chem. Soc.,* 2008, **130**, 8455-8459.

104 A. Bowers, N. West, J. Taunton, S. L. Schreiber, J. E. Bradner and R. M. Williams, *J. Am. Chem. Soc.,* 2008, **130**, 11219-11222.

105 Y. Chen, C. Gambs, Y. Abe, P. J. Wentworth and K. D. Janda, *J. Org. Chem.,* 2003, **68**, 8902-8905.

106 Y. Masuoka, A. Nagai, K. Shin-ya, K. Furihata, K. Nagai, K. -. Suzuki, Y. Hayakawa and H. Seto, *Tetrahedron Lett.,* 2001, **42**, 41-44.

107 L. Salvador and H. Luesch, *Curr. Drug Targets,* 2012, **13**, 1029-1047.

108 H. Nakajima, Y. B. Kim, H. Terano, M. Yoshida and S. Horinouchi, *Expt. Cell. Res.,* 1998, **241**, 126-133.

109 Y. Ying, Y. Liu, S. R. Byeon, H. Kim, H. Luesch and J. Hong, *Org. Lett.,* 2008, **10**, 4021-4024.

110 K. E. Cole, D. P. Dowling, M. A. Boone, A. J. Phillips and D. W. Christianson, *J. Am. Chem. Soc.,* 2011, **133**, 12474-12477.

111 Y. Liu, L. A. Salvador, S. Byeon, Y. Ying, J. C. Kwan, B. K. Law, J. Hong and H. Luesch, *J. Pharmacol. Exp. Ther.,* 2010, **335**, 351-361.

112 M. E. Law, P. E. Corsino, S. C. Jahn, B. J. Davis, S. Chen, B. Patel, K. Pham, J. Lu, B. Sheppard, P. Nørgaard, J. Hong, P. Higgins, J. S. Kim, H. Luesch and B. K. Law, *Oncogene,* 2013, **32**, 1316-1329.

113 S. U. Lee, H. B. Kwak, S. H. Pi, H. K. You, S. R. Byeon, Y. Ying, H. Luesch, J. Hong and S. H. Kim, *ACS Med. Chem. Lett.,* 2011, **2**, 248-251.

114 Y. Liu, Z. Wang, J. Wang, W. Lam, S. Kwong, F. Li, S. L. Friedman, S. Zhou, Q. Ren, Z. Xu, X. Wang, L. Ji, S. Tang, H. Zhang, E. L. Lui and T. Ye, *Liver Int.,* 2013, **33**, 504-515.

115 L. A. Salvador, H. Park, F. H. Al-Awadhi, Y. Liu, B. Kim, S. L. Zeller, Q. Chen, J. Hong and H. Luesch, *ACS Med. Chem. Lett.,* 2014, **5**, 905-910..

116 B. Kim, H. Park, L. A. Salvador, P. E. Serrano, J. C. Kwan, S. L. Zeller, Q. Y. Chen, S. Ryu, Y. Liu, S. Byeon, H. Luesch and J. Hong, *Bioorg. Med. Chem. Lett.,* 2014, **24**, 3728-3731.

117 M. W. B. McCulloch, G. S. Coombs, N. Banerjee, T. S. Bugni, K. M. Cannon, M. K. Harper, C. A. Veltri, D. M. Virshup and C. M. Ireland, *Bioorg. Med. Chem.,* 2009, **17**, 2189-2198.

118 D. Ungermannova, S. J. Parker, C. G. Nasveschuk, W. Wang, B. Quade, G. Zhang, R. D. Kuchta, A. J. Phillips and X. Liu, *PLoS One,* 2012, **7**, e29208.

119 A. Balcerczyk and L. Pirola, *Biofactors,* 2010, **36**, 383-393.

120 M. Gutierrez, E. H. Andrianasolo, W. K. Shin, D. E. Goeger, A. Yokochi, J. Schemies, M. Jung, D. France, S. Cornell-Kennon, E. Lee and W. H. Gerwick, *J. Org. Chem.,* 2009, **74**, 5267-5275.

121 A. F. Kisselev, W. A. van der Linden and H. S. Overkleeft, *Chem. Biol.,* 2012, **19**, 99-115.

122 G. Nalepa, M. Rolfe and J. W. Harper, *Nat. Rev. Drug Discov.,* 2006, **5**, 596-613.

123 A. R. Pereira, A. J. Kale, A. T. Fenley, T. Byrum, H. M. Debonsi, M. K. Gilson, F. A. Valeriote, B. S. Moore and W. H. Gerwick, *ChemBioChem,* 2012, **13**, 810-817.

124 K. B. Kim and C. M. Crews, *Nat. Prod. Rep.,* 2013, **30**, 600-604.

125 K. Suenaga, T. Mutou, T. Shibata, T. Itoh, H. Kigoshi and K. Yamada, *Tetrahedron Lett.,* 1996, **37**, 6771-6774.

126 K. Suenaga, T. Mutou, T. Shibata, T. Itoh, T. Fujita, N. Takada, K. Hayamizu, M. Takagi, T. Irifune, H. Kigoshi and K. Yamada, *Tetrahedron,* 2004, **60**, 8509-8527.

127 B. Han, H. Gross, D. E. Goeger, S. L. Mooberry and W. H. Gerwick, *J. Nat. Prod.,* 2006, **69**, 572-575.

128 A. Tripathi, J. Puddick, M. R. Prinsep, M. Rottmann and L. T. Tan, *J. Nat. Prod.,* 2010, **73**, 1810-1814.

129 A. Tripathi, J. Puddick, M. R. Prinsep, M. Rottmann, K. P. Chan, D. Y. Chen and L. T. Tan, *Phytochemistry (Elsevier),* 2011, **72**, 2369-2375.

130 L. Dai, B. Chen, H. Lei, Z. Wang, Y. Liu, Z. Xu and T. Ye, *Chem. Commun.,* 2012, **48**, 8697-8699.

131 J. Kimura, Y. Takada, T. Inayoshi, Y. Nakao, G. Goetz, W. Y. Yoshida and P. J. Scheuer, *J. Org. Chem.,* 2002, **67**, 1760-1767.

132 Y. Nakao, W. Y. Yoshida, Y. Takada, J. Kimura, L. Yang, S. L. Mooberry and P. J. Scheuer, *J. Nat. Prod.,* 2004, **67**, 1332-1340.

133 S. Sato, A. Murata, T. Orihara, T. Shirakawa, K. Suenaga, H. Kigoshi and M. Uesugi, *Chem. Biol.,* 2011, **18**, 131-139.

134 J. Zhang, P. L. Yang and N. S. Gray, *Nat. Rev. Cancer,* 2009, **9**, 28-39.

135 J. Rauch, N. Volinsky, D. Romano and W. Kolch, *Cell. Commun. Signal.,* 2011, **9**, 23.

136 P. Lahiry, A. Torkamani, N. J. Schork and R. A. Hegele, *Nat. Rev. Genet.,* 2010, **11**, 60-74.

137 T. Teruya, H. Sasaki, H. Fukazawa and K. Suenaga, *Org. Lett.,* 2009, **11**, 5062-5065.

138 C. S. Stevenson, E. A. Capper, A. K. Roshak, B. Marquez, C. Eichman, J. R. Jackson, M. Mattern, W. H. Gerwick, R. S. Jacobs and L. A. Marshall, *J. Pharmacol. Exp. Ther.,* 2002, **303**, 858-866.

139 M. Steegmaier, M. Hoffmann, A. Baum, P. Lénárt, M. Petronczki, M. Krssák, U. Gürtler, P. Garin-Chesa, S. Lieb, J. Quant, M. Grauert, G. R. Adolf, N. Kraut, J. M. Peters and W. J. Rettig, *Curr. Biol.,* 2007, **17**, 316-322.

140 V. Antoniades, A. Sioga, E. M. Dietrich, S. Meditskou, L. Ekonomou and K. Antoniades, *Med. Hypotheses,* 2013, **81**, 1159-1163.

141 G. J. Brewer, R. D. Dick, D. K. Grover, V. LeClaire, M. Tseng, M. Wicha, K. Pienta, B. G. Redman, T. Jahan, V. K. Sondak, M. Strawderman, G. LeCarpentier and S. D. Merajver, *Clin. Cancer Res.,* 2000, **6**, 1-10.

142 V. Antoniades, A. Sioga, E. M. Dietrich, S. Meditskou, L. Ekonomou and K. Antoniades, *Med. Hypotheses,* 2013, **81**, 1159-1163.

143 J. C. Kwan, J. R. Rocca, K. A. Abboud, V. J. Paul and H. Luesch, *Org. Lett.,* 2008, **10**, 789-792.

144 J. C. Kwan, R. Ratnayake, K. A. Abboud, V. J. Paul and H. Luesch, *J. Org. Chem.,* 2010, **75**, 8012-8023.

145 L. A. Morris, B. F. Milne, G. S. Thompson and M. Jaspars, *J. Chem. Soc. Perkin Trans.,* 2002, **2**, 1072-1075.

146 R. Latifi, M. Bagherzadeh, B. F. Milne, M. Jaspars and S. P. de Visser, *J. Inorg. Biochem.,* 2008, **102**, 2171-2178.

147 H. Liu, Y. Liu, Z. Wang, X. Xing, A. R. Maguire, H. Luesch, H. Zhang, Z. Xu and T. Ye, *Chem. Eur. J.,* 2013, **19**, 6774-6784.

148 J. C. Kwan, Y. Liu, R. Ratnayake, R. Hatano, A. Kuribara, C. Morimoto, K. Ohnuma, V. J. Paul, T. Ye and H. Luesch, *ChemBioChem,* 2014, **15**, 799-804.

149 U. Matern, C. Schelberger, S. Jelakovic, J. Weckesser and G. E. Schulz, *Chem. Biol.,* 2003, **10**, 997-1001.

150 L. A. Salvador, K. Taori, J. S. Biggs, J. Jakoncic, D. A. Ostrov, V. J. Paul and H. Luesch, *J. Med. Chem.,* 2013, **56**, 1276-1290.

151 A. Y. Lee, T. A. Smitka, R. Bonjouklian and J. Clardy, *Chem. Biol.,* 1994, **1**, 113-117.

152 K. Taori, S. Matthew, J. R. Rocca, V. J. Paul and H. Luesch, *J. Nat. Prod.,* 2007, **70**, 1593-1600.

153 P. J. Barnes and R. A. Stockley, *Eur. Respir. J.,* 2005, **25**, 1084-1106.

154 J. C. Kwan, E. A. Eksioglu, C. Liu, V. J. Paul and H. Luesch, *J. Med. Chem.,* 2009, **52**, 5732-5747.

155 S. Conus and H. U. Simon, *Swiss Med. Wkly.,* 2010, **140**, w13042.

156 S. Yang, W. Zhang, N. Ding, J. Lo, Y. Liu, M. J. Clare-Salzler, H. Luesch and Y. Li, *Bioorg. Med. Chem.,* 2012, **20**, 4774-4780.

157 T. F. Molinski, K. A. Reynolds and B. I. Morinaka, *J. Nat. Prod.,* 2012, **75**, 425-431.

158 P. G. Williams, W. Y. Yoshida, R. E. Moore and V. J. Paul, *J. Nat. Prod.,* 2003, **66**, 1006-1009.

159 T. Sun, W. Zhang, C. Zong, P. Wang and Y. Li, *J. Pept. Sci.,* 2010, **16**, 364-374.

160 Y. Liu, W. Zhang, L. Li, L. A. Salvador, T. Chen, W. Chen, K. M. Felsenstein, T. B. Ladd, A. R. Price, T. E. Golde, J. He, Y. Xu, Y. Li and H. Luesch, *J. Med. Chem.,* 2012, **55**, 10749-10765.

161 J. Orjala, D. G. Nagle, V. L. Hsu and W. H. Gerwick, *J. Am. Chem. Soc.,* 1995, **117**, 8281-8282.

162 F. W. Berman, W. H. Gerwick and T. F. Murray, *Toxicon,* 1999, **37**, 1645-1648.

163 L. M. Nogle, T. Okino and W. H. Gerwick, *J. Nat. Prod.,* 2001, **64**, 983-985.

164 W. I. Li, F. W. Berman, T. Okino, F. Yokokawa, T. Shioiri, W. H. Gerwick and T. F. Murray, *Proc. Natl. Acad. Sci. USA,* 2001, **98**, 7599-7604.

165 Z. Cao, W. H. Gerwick and T. F. Murray, *BMC Neuroscience,* 2010, **11**, 154-166.

166 S. V. Jabba, A. Prakash, S. M. Dravid, W. H. Gerwick and T. F. Murray, *J. Pharmacol. Expt. Ther.,* 2010, **332**, 698-709.

167 A. Pereira, Z. Cao, T. F. Murray and W. H. Gerwick, *Chem. Biol.,* 2009, **16**, 893-906.

168 H. Choi, A. R. Pereira, Z. Cao, C. F. Shuman, N. Engene, T. Byrum, T. Matainaho, T. F. Murray, A. Mangoni and W. H. Gerwick, *J. Nat. Prod.,* 2010, **73**, 1411-1421.

169 K. L. Malloy, H. Choi, C. Fiorilla, F. A. Valeriote, T. Matainaho and W. H. Gerwick, *Bioorg. Med. Chem. Lett.,* 2012, **22**, 683-688.

170 M. Wu, T. Okino, L. M. Nogle, B. L. Marquez, R. T. Williamson, N. Sitachitta, F. W. Berman, T. F. Murray, K. McGough, R. Jacobs, K. Colsen, T. Asano, F. Yokokawa, T. Shioiri and W. H. Gerwick, *J. Am. Chem. Soc.,* 2000, **122**, 12041-12042.

171 K. T. LePage, D. Goeger, F. Yokokawa, T. Asano, T. Shioiri, W. H. Gerwick and T. F. Murray, *Toxicol. Lett.,* 2005, **158**, 133-139.

172 A. R. Pereira, Z. Cao, N. Engene, I. E. Soria-Mercado, T. F. Murray and W. H. Gerwick, *Org. Lett.,* 2010, **12**, 4490-4493.

173 I. E. Soria-Mercado, A. Pereira, Z. Cao, T. F. Murray and W. H. Gerwick, *Org. Lett.,* 2009, **11**, 4704-4707.

174 D. J. Edwards, B. L. Marquez, L. M. Nogle, K. McPhail, D. E. Goeger, M. A. Roberts and W. H. Gerwick, *Chem. Biol.,* 2004, **11**, 817-833.

175 J. Müller and A. Hemphill, *Int. Rev. Cell Mol. Biol.,* 2013, **301**, 359-401.

176 S. R. Wilkinson and J. M. Kelly, *Expert Rev. Mol. Med.,* 2009, **11**, e31.

177 D. Hughes, *Nat. Rev. Genet.,* 2003, **4**, 432-441.

178 R. G. Linington, B. R. Clark, E. E. Trimble, A. Almanza, L. Urena, D. E. Kyle and W. H. Gerwick, *J. Nat. Prod.,* 2009, **72**, 14-17.

179 T. Conroy, J. T. Guo, R. G. Linington, N. H. Hunt and R. J. Payne, *Chem. Eur. J,* 2011, **17**, 13544-13552.

180 T. Conroy, J. T. Guo, N. H. Hunt and R. J. Payne, *Org. Lett.,* 2010, **12**, 5576-5579.

181 S. C. Stolze, E. Deu, F. Kaschani, N. Li, B. I. Florea, K. H. Richau, T. Colby, R. A. van der Hoorn, H. S. Overkleeft, M. Bogyo and M. Kaiser, *Chem. Biol.,* 2012, **19**, 1546-1555.

182 B. Miller, A. J. Friedman, H. Choi, J. Hogan, J. A. McCammon, V. Hook and W. H. Gerwick, *J. Nat. Prod.,* 2014, **77**, 92-99.

183 L. M. Sanchez, D. Lopez, B. A. Vesely, G. Della Togna, W. H. Gerwick, D. E. Kyle and R. G. Linington, *J. Med. Chem.,* 2010, **53**, 4187-4197.

184 L. M. Sanchez, G. M. Knudsen, C. Helbig, G. De Muylder, S. M. Mascuch, Z. B. Mackey, L. Gerwick, C. Clayton, J. H. McKerrow and R. G. Linington, *J. Nat. Prod.,* 2013, **76**, 630-641.

185 M. B. Miller and B. L. Bassler, *Annu. Rev. Microbiol.,* 2001, **55**, 165-199.

186 V. C. Kalia, *Biotech. Adv.,* 2013, **31**, 224-245.

187 S. Dobretsov, M. Teplitski, A. Alagely, S. P. Gunasekera and V. J. Paul, *Environ. Microbiol. Rep.,* 2010, **2**, 739-744.

188 B. R. Clark, N. Engene, M. E. Teasdale, D. C. Rowley, T. Matainaho, F. A. Valeriote and W. H. Gerwick, *J. Nat. Prod.,* 2008, **71**, 1530-1537.

189 J. C. Kwan, T. Meickle, D. Ladwa, M. Teplitski, V. J. Paul and H. Luesch, *Mol. Biosyst.,* 2011, **7**, 1205-1216.

190 H. Choi, S. J. Mascuch, F. A. Villa, T. Byrum, M. E. Teasdale, J. E. Smith, L. B. Preskitt, D. C. Rowley, L. Gerwick and W. H. Gerwick, *Chem. Biol.,* 2012, **19**, 589-598.

191 R. Montaser, V. J. Paul and H. Luesch, *Org. Lett.,* 2013, **15**, 4050-4053.

192 J. C. Kwan and H. Luesch, *Chem. Eur. J.,* 2010, **16**, 13020-13029.

NPR

ARTICLE

Fig. 1 The structure of brentuximab vedotin (Adcetris). The small molecule portion, monomethyl auristatin E, is designed based on the cyanobacterial molecule dolastatin 10.

Fig. 2. Screening platforms for bioactivity assessment, mechanism of action and target identification of small molecules from marine cyanobacteria.

Fig. 3 MOA of tubulin-targeting agents. Tubulin-disrupting compounds from marine cyanobacteria cause significant cellular microtubule depolymerization, leading to G2 cell cycle arrest and cell death.

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.

Vinca domain binding agents

Dolastatin 10   R = H
Symplostatin 1   R = Me

	R¹	R²	R³
Symplostatin 3	H	Me	CO_2H
Malevamide D	Me	H	CH_2OH

Belamide A

	R¹	R²
Cryptophycin-1	CH_3	Cl
Cryptophycin-24	H	H

Colchicine domain binding agent

Curacin A

Fig. 4 Tubulin-disrupting agents from marine cyanobacteria.

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.

Fig. 5 Actin-targeting agents from marine cyanobacteria.

J. Name., 2012, **00**, 1-3 | **25**

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.

Fig. 6 Small molecules from marine cyanobacteria acting on non-classical cancer cell targets.

Fig. 7 MOA of HDAC inhibitors. Cell cycle arrest and apoptosis mediated by HDAC inhibitors are in part due to alteration in gene expression arising from changes in acetylation levels of histone and non-histone proteins.

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.

MOA: DPP8 inhibition and chelation of Cu²⁺ and Zn²⁺

Grassypeptolide A

MOA: Elastase inhibition

Lyngbyastatin 7

Lyngbyastatin 4

Symplostatin 5

Fig. 8 Selective DPP8 and elastase inhibitors from marine cyanobacteria. The 2-amino-butenoic acid moiety (red) of modified cyanobacterial cyclodepsipeptides serves as the warhead in inhibiting elastase while other modified amino acid residues (blue) provides additional key interactions.

Fig. 9 MOA of elastase inhibitors from marine cyanobacteria. Elastase inhibitors from marine cyanobacteria modulate the transcriptional and post-translational effects of elastase in bronchial epithelial cells leading to significant cytoprotection from elastase-induced cell detachment and anti-proliferation.

Fig. 10 Structure and bioactivity of cathepsin E inhibitors. **A**. Cathepsin E inhibitors from marine cyanobacteria. **B**. Selectivity profile of grassystatin A against metalloproteases and aspartic proteases. Grassystatin A did not inhibit members of other families of proteases such as serine and cysteine proteases, dipeptidyl/tripeptidyl peptidases and cysteine carboxypeptidases. **C**. Key molecular interactions between grassystatin A and cathepsin E. Reprinted with permission from J. C. Kwan, E. A. Eksioglu, C. Liu, V. J. Paul and H. Luesch, *J. Med. Chem.,* 2009, **52**, 5732-5747. Copyright 2009 American Chemical Society.

Fig. 11 Design of new BACE1 inhibitor based on the cyanobacterial compound tasiamide B.

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.

Fig. 12 Structures of modulators of voltage-gated ion channels from marine cyanobacteria.

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.

Antimalarial

MOA: Inhibition of plasmodial falcipains

Symplostatin 4/Gallinamide A

Anti-trypanosomal

MOA: Disruption of glycosomal functions of kinetoplastid parasites

Almiramide C

Fig. 13 Protozoal-targeting compounds from marine cyanobacteria and their MOA.

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.


Fig. 14 Structures of quorum sensing inhibitors from marine cyanobacteria.

RSC Author Templates - ChemDraw (CDX) - Annual Reports/SPR Artwork

All text and images must be placed within the frame.

Fig.15 Bifunctional molecules from marine cyanobacteria and the MOA pitinoic acid B and the corresponding component fatty acids.